A SIMULATION MODEL FOR BLOOD CHOLESTEROL DYNAMICS AND RELATED DISORDERS

by

Emre Muzaffer Demirezen

B.S., Industrial Engineering, Boğaziçi University, 2006

Submitted to the Institute for Graduate Studies in
Science and Engineering in partial fulfillment of
the requirements for the degree of
Master of Science

Graduate Program in Industrial Engineering
Boğaziçi University
2009

ABSTRACT

A SIMULATION MODEL FOR BLOOD CHOLESTEROL DYNAMICS AND RELATED DISORDERS

Cholesterol metabolism and other factors affecting its dynamics comprise a complex system which includes genetics of the person, diet, exercise, and drugs. High concentrations of cholesterol are related with higher risk of cardiovascular diseases, therefore cholesterol is the subject of many modeling studies. The purpose of these studies is generally identifying or quantifying some parameters, or testing some hypothesis about cholesterol mechanism. Focus of the simulation models are mostly at the cellular level, whereas mathematical models usually make several assumptions for the sake of analytical tractability. As such, these types of models do not typically adopt a systemic view.

In this study, system dynamics method, which has a systemic view that other cholesterol studies lack, is employed in modeling and analyzing the dynamics of cholesterol metabolism. The goal of this thesis study is to construct a continuous dynamic simulation model that can generate long term dynamics of cholesterol in healthy and hypercholesterolemic subjects, taking into account body weight dynamics, diet, and exercise of the person. For both healthy and hypercholesterolemic subjects the model is able to generate realistic behaviors of different types of blood cholesterol, and body weight. In the scenario analysis section it is shown that a person can have healthier cholesterol levels by changing her/ his diet and/or doing more exercise. Also it's observed that exercise is more effective than diet even in the case when the subject does not lose weight. In the case of hypercholesterolemic patients, the model effectively mimics the way the drugs work and shows how the patient can reach healthier cholesterol levels.

ÖZET

KAN KOLESTEROLÜ DİNAMİKLERİ VE İLGİLİ HASTALIKLAR ÜZERİNE BİR DİNAMİK SİMULASYON MODELİ

Kolesterol metabolizması ve kolesterol dinamiklerini etkileyen faktörler kişinin genetik özelliklerini, diyetini, egzersiz ve ilaçlarını içeren karmaşık bir sistemdir. Yüksek kolesterol konsantrasyonları yüksek kalp-damar hastalıkları riskiyle ilişkili olduğu için kolesterol birçok modelleme çalışmasının konusu olmuştur. Bu çalışmaların amacı genellikle bazı parametreleri belirlemek, ölçmek ya da kolesterol mekanizması hakkındaki bazı hipotezleri test etmektir. Simulasyon modellerinin odağı genelde hücresel düzeydedir, matematiksel modeller ise analitik çözülebilirlik uğruna pekçok varsayım içerirler. Yani her iki tip model de genellikle bütüncül (sistemik) bir bakış açısına sahip değildir.

Bu çalışmada, tipik kolesterol çalışmalarında olmayan bütüncül bir yaklaşıma sahip olan sistem dinamikleri yöntemi, kolesterol metabolizmasının dinamiklerini modellemek ve anlamak için kullanılmıştır. Bu tez çalışmasının amacı, sağlıklı ya da yüksek kolesterole sahip hastalarda, vücut ağırlığı dinamiklerini, diyet ve egzersiz düzeylerini hesaba katıp uzun dönemli kolesterol dinamiklerini oluşturabilecek sürekli-zamanlı bir simulasyon modeli kurmaktır. Değişik tipteki kan kolesterollerinin ve vücut ağırlığının davranışları hem sağlıklı hem de yüksek kolesterole sahip hastalarda model tarafından oluşturulabilmiştir. Bir kişinin diyetini değiştirerek ve/veya daha fazla egzersiz yaparak daha sağlıklı kolesterol düzeylerine ulaşabileceği senaryo analizi kisminda gösterilmiştir. Ayrıca kişi kilo vermese bile, egzersiz yapmanın diyet yapmaktan daha etkili olduğu gözlenmiştir. Yüksek tansiyona sahip hastalarda ise, model ilaçların nasıl çalıştığını etkin bir şekilde temsil etmiş ve hastaların daha sağlıklı kolesterol seviyelerine nasıl ulaşabileceğini göstermiştir.

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF TABLES

1. INTRODUCTION AND LITERATURE SURVEY

Human body is a complex system that has enormous number of tissues and cells that work in accordance to sustain proper functioning of the body (homeostasis). Different parts of the body have different jobs or characteristics; but, through blood, all of them must receive micronutrients from the central system for their metabolic or structural needs. Some of these micronutrients such as glucose, fatty acids, and amino acids are required in large amounts. Though needed in minimal amounts, cholesterol is no less vital than others but higher blood concentrations of cholesterol is shown to be related with higher risk of cardiovascular diseases, which are the leading cause of the deaths in the Western culture (Glass & Witztum, 2001). Therefore, balancing the blood cholesterol level, or generally keeping it lower than dangerous levels, is an important issue.

Cholesterol is a fatlike, waxy substance, which is used and found in tissues and plasma either as free cholesterol or in its storage form cholesterol ester. Cholesterol is essential for the survival. This lipid is found in parts of the outer membrane that surrounds every cell and used to produce hormones, vitamin D, and bile acids that are essential in digesting fat. (Murray, Granner, & Rodwell, 2006)

Cholesterol is synthesized virtually within all of the nucleated cells. The liver also synthesizes cholesterol and sends it to the peripheral tissues via the blood stream. Since cholesterol, like other lipids, is insoluble in water it is bound to blood lipoproteins for its transport. Low-density lipoprotein (LDL) is responsible for the uptake of cholesterol from liver to the other tissues. High-density lipoprotein (HDL) removes free cholesterol from the tissues and arteries and takes them back to the liver. (Murray, Granner, & Rodwell, 2006; Bhagavan, 2002 ;Guyton, et al., 1991)

Cholesterol is rich in foods of animal origin like eggs and meat. Most of the absorbed cholesterol is esterified with fatty acids and incorporated into chylomicrons that enter the blood through the lymph. Chylomicrons unload most of their triacylglycerols to peripheral tissues like muscle or adipose tissue, where they are burned for their energy, or stored as fat respectively. Liver then rapidly takes up chylomicron remnants. Thus, liver takes up

nearly all of the dietary cholesterol. This process is a feedback mechanism that suppresses cholesterol production in the liver. Although other sites such as intestinal tract, adrenal cortex, testes, and skin can also synthesize cholesterol, their contribution is not very important. (Bhagavan, 2002)

Very-low density lipoprotein, or VLDL, is the vehicle of transport of triacylglycerols from the liver to the other tissues. Its metabolism is similar to that of chylomicron's. Reaction with the extrahepatic tissues results in the loss of most of the triacylglycerols in the VLDL. The resulting remnant is called intermediate-density lipoprotein, or IDL. The liver takes about half of the IDL up while the other half is converted to low-density lipoprotein, or LDL, which is rather rich in cholesterol. (Bhagavan, 2002; Murray, Granner, & Rodwell, 2006)

Because LDLs are the remnants of the remnants of the VLDLs in the blood, the density of LDL in the blood is determined by the rate of VLDL secreted from the liver. Hepatic triacylglycerol synthesis is followed immediately by the formation and secretion of VLDLs. In humans, the fatty acids used in this process are mainly from the uptake of free fatty acids from the circulation.

High-density lipoproteins are synthesized and secreted from the liver and intestines. HDL acts as a repository for apo C and apo E molecules that are required in the metabolism of chylomicrons and VLDL. HDL also has part in the removal of excess unesterified cholesterol from lipoproteins and tissues. The class B scavenger receptor B1 (SR-B1) is an HDL receptor that has dual role in HDL metabolism. In the liver and steroidogenic tissues, it selectively uptakes cholesteryl ester to the cells; while in the tissues SR-B1 mediates the acceptance of cholesterol from the cells to the HDL. HDL transports these cholesterols to the liver for excretion via bile or bile acids. Absorption of bile and bile acids back from the intestines to the liver is thus an important determining factor of cholesterol pool in the liver. This process is known as reverse cholesterol transport, or RCT (Murray, Granner, & Rodwell, 2006). Because HDL lowers the amount of cholesterol in the extrahepatic tissues, extrahepatic tissues become more willing to take up cholesterol from blood which is mainly from LDL. Thus increased levels of HDL or HDL choleterol have an indirect effect on LDL cholesterol stocks in the blood.

Cholesterol is an important factor in the formation of gallstones. However, its major harmful role is in the development of atherosclerosis of vital arteries, which leads to heart attacks, brain strokes, and some other peripheral vascular diseases. (Stein & Stein, 1999; Tall, 1990)

Atherosclerosis is found to be correlated with the high concentrations of low-density lipoprotein, or LDL. (Gotto Jr., Lenfant, Paoletti, & Catapano, 1997; Ylä-Herttuala, et al., 1989) An independent risk factor is low levels of high-density lipoprotein, or HDL (Ohashi, Mu, Wang, Yao, & Chen, 2005; Barter, Kastelein, Nunn, & Richard, 2003). Also, the ratio of LDL to HDL - the higher the riskier- is regarded as a risk factor in some studies. (Murray, Granner, & Rodwell, 2006)

Because atherosclerosis is related to HDL density lower than 60 mg/dl and LDL density higher than100 mg/dL, people are advised to keep their HDL and LDL within safe limits (HDL> 60 mg/dL, LDL< 100mg/dL). Borderline high and low levels are also defined for LDL as 130 mg/dL and for HDL as 40 mg/dL (Ma, 2006).

People who have cholesterol levels in the upper 5-10% of the whole population are considered to have a lipoprotein - associated disorder (Bhagavan, 2002). Hyperlipoproteinemias are considered in two groups: primary and secondary. The first class is stemming from genetic disorders, whereas some causes of the latter are diabetes mellitus, hypothyroidism, nephrotic syndrome, uremia, ethanol abuse, primary biliary cirrhosis, and intake of oral contraceptives. Primary disorders of hyperlipoproteinemias include familial lipoprotein lipase deficiency (type I), familial hypercholesterolemia (type IIa), familial dysbetalipoproteinemia (type III), familial hypertriacylglycerolemia (type IV), familial hyperalphalipoproteinemia, hepatic lipase deficiency, familial LCAT deficiency, familial lipoprotein (a) excess (Murray, Granner, & Rodwell, 2006).

Familial hypercholesterolemia (FH) is amongst the most common lipoprotein disorders. It results from a genetic problem in which LDL receptors of a patient are partly or mostly defective and not functioning. FH heterozygotes have normal levels of HDL and triacylglycerol, yet their LDL cholesterol levels are generally between 320 and 500 mg/dL

(Bhagavan, 2002). Residence time of LDL may increase up to 2.5 times the normal values; this is mostly due to the decreased functionality of the LDL receptors. IDLs are also taken up from the LDL receptors, so their longer residence times become a secondary cause of the higher LDL concentrations.

Though the most significant determinants of cholesterol in blood are of hereditary nature, there are numerous dietary and environmental factors. These can be listed as diet, exercise, drugs, and stress.

Diet has a direct effect on blood cholesterol levels. Taking too much cholesterol and saturated fatty acids instead of taking polyunsaturated and monounsaturated fatty acids tends to increase blood LDL levels (Dietschy, Turley, & Spady, 1993). Also bile acids, which are secreted from cholesterol of liver origin, are a determining factor on the blood levels of cholesterol. They affect how much cholesterol and fatty acids are absorbed in the intestines and because they are of cholesterol origin, their loss via feces affects how much bile and bile acids will be secreted from cholesterol in the liver. Thus high fiber diets, which increase the loss and decrease the effectiveness of bile and bile acids in the intestines, have a two-fold effect on the cholesterol metabolism. First they determine how much new cholesterol and fatty acid will be absorbed in the intestines, and second they decrease the cholesterol pool in the liver by increasing bile loss to feces. (Murray, Granner, & Rodwell, 2006; Lin & Connor, 1980)

Exercise, depending on its intensity and frequency, has a positive effect on the cholesterol levels in the blood. In most of the studies, it has increased blood HDL levels. Though the reason behind this favorable dynamic is not very clear, it has been shown that exercise has also a role in modifying the HDL particles so that their anti-atherogenic qualities are improved. (Halverstadt, Phares, Wilund, Goldberg, & Hagberg, 2007; Olchawa, et al., 2004; Marrugat, Elosua, Covas, Molina, & Rubies-Prat, 1996)

Stress has a two-fold effect on the cholesterol mechanism. First, it is known that the body releases some hormones to the blood in different phases of the stressed period. These hormones include epinephrine, norepinephrine, cortisone, and cortisol. Especially cortisone has metabolic effects on the lipids and adipose tissue. It has indirect effect over how much

free fatty acid is released from the adipose tissue. Because free fatty acids in the blood determine the levels of VLDL secretion from the liver, and VLDL affects how much LDL is going to be present in the blood; one can argue that human stress has a role in the levels of blood cholesterol in humans.

Besides these hormone driven effects, stress may have an indirect commitment effect on whether or not to continue to the healthy diet and adequate exercise. This commitment to the diet and exercise programs can be in two ways. Depending on the nature of the person, one may devote more of his or her energy to continue to the program; or he or she may abandon partly or completely the program. The sources of the stress component mentioned in this paragraph is stemming from the test results of the blood cholesterols together from the weariness effect of continuing to the diet and exercise.

There are several types of medication for cholesterol disorders. The most practiced types are statin and niacin related drugs. Statin group interfere with the ability of the liver to synthesize cholesterol by blocking some necessary enzymes. Moreover, statins increase the uptake of blood cholesterols to the liver by increasing LDL-receptor activity. On the other hand, niacin group are insoluble powders that bind to bile in the intestine and lower their absorption rate back to liver. Thus, cholesterol pool in the liver is reduced and the liver takes up more cholesterol from the blood to compensate for this loss. (Bhagavan, 2002; Murray, Granner, & Rodwell, 2006)

But these drugs come with their costs. Niacin group are gritty powders and they must be consumed in large amounts. In most of the patients, niacin group cause flushing, hyper-pigmentation, diarrhea, liver function abnormalities, and nausea. On the other hand, statin inhibits HMG-CoA reductase, which plays a role in synthesis of many products vital for cellular metabolism. Thus, toxicity is an issue in statin therapy and its long-term dynamics is not known. (Bhagavan, 2002)

Additional factors that affect blood cholesterol levels include body weight, smoking, male gender, diabetics, obesity, high blood pressure, drinking soft as opposed to hard water, thyroid disorders, and some other hormonal deficiencies. (Murray, Granner, & Rodwell, 2006)

Cholesterol and the dynamics of the lipoprotein metabolism are the subjects of many studies. 17 Nobel prizes have been given to researchers who have made significant contributions to the understanding of cholesterol and its metabolism. Some studies are made in the molecular level, whereas some other studies are merely statistical approaches that explore the results of experiments.

Moreover, there are several modeling studies about the cholesterol metabolism in the literature. It is possible to group them in terms of both purpose and methodology. Their purpose, generally, is either identifying/quantifying some parameters, or testing alternative hypothesis about the underlying structure of the cholesterol mechanism/ metabolism (Schwartz, Zech, VandenBroek, & Cooper, 1993). In terms of methodology, there are simulation models and mathematically-analyzable models (August, Parker, & Barahona, 2007). Simulation models are mostly at the cellular level and generally lack a systemic point of view. On the other hand, mathematically-analyzable models include several assumptions for the sake of analytical tractability, but this fact raises questions about the validity of such models. Thus there seems to be a need for systemic simulation modeling of cholesterol dynamics that does not compromise model realism for the sake of mathematical tractability.

After stating the research objectives in the following section, the system dynamics model will be presented with emphasis on its structure. Next, the validity of the model will be discussed and the base behavior of the model will be analyzed for a healthy patient case. In the scenario analysis section, a cholesterol disorder, medication, different diets and exercise programs will be explored. Finally in the conclusion part, the findings will be listed together with future work suggestions.

2. METHODOLOGY AND RESEARCH OBJECTIVES

Cholesterol metabolism and those factors affecting its dynamics comprise a complex system. There are nonlinear interactions of numerous agents and subsystems, inherent delays or memory of the history, and a multi segmented structure. This complexity makes hard, and most of the time impossible to analytically track and predict the behavior of the system, unless many simplifications are made.

System dynamics is a methodology and an approach that helps in understanding this kind of complexity. It deals with internal feedback loops and time delays that affect the behavior of the entire system using continuous-time simulation. What makes using system dynamics different from other approaches in studying complex systems is the use of feedback loops, stocks, and flows. Its aim is to test a dynamic hypothesis about the behavior of specific variables in a complex system. System dynamics models are constructed to represent the interactions in a system so that, the behavioral change in the outputs due to the changes in the inputs are meaningful and causal.

The complexity, which is brought about by the nature of the human body, can thus be handled with system dynamics methodology. In this MS Thesis study, system dynamics is used in trying to understand the dynamics of cholesterol metabolism in human as affected by the diet, exercise, drugs, and the genetics of the person itself.

The purpose of this thesis study is to construct and analyze a dynamic model of cholesterol balance in the blood stream in order to have reduced risk of atherosclerosis. The person who is assumed to be in the borderline or high-risk group of atherosclerosis may consider lowering his or her cholesterol levels in a number of ways like changing diet, exercise, taking drugs, or any combination of these. As explained in the introduction section, though medication has favorable results on the blood cholesterol levels, they come with some side or unknown effects both in the short and long period. Difficulty of patient's sticking to strict diets or exercise programs is another problem. So the constructed model tries to answer the following question: "Are there efficient mixes of diet, exercise and minimal medication to keep blood cholesterol levels within safe limits?" The study will

take into consideration the people's selection of different diets, exercise programs, taking medication; and the genetic disorders that may result in higher cholesterol levels, ceteris paribus.

3. OVERVIEW OF THE MODEL

The relationships between important factors that affect cholesterol levels in blood can be seen in Figure 3.1 and Figure 3.2 at a macro level. For simplicity the model is divided into six sectors. These are liver, blood, extrahepatic tissues, diet & exercise, digestive system, and body weight sectors. All of these sectors are analyzed in detail in the next chapter. In a nutshell, liver sector defines relationships which synthesize blood cholesterol and regulate cholesterol uptake from blood. Blood sector includes relationships about transportation of cholesterol among lipoproteins, liver and extrahepatic tissues. Extrahepatic tissue sector defines relationships that regulate cholesterol uptake from blood lipoproteins. Diet & exercise sector represents diet and exercise, together with their effects on digestive system and body weight. Digestive system sector includes relationships about absorbed nutrients and their effects on blood cholesterol levels and reverse cholesterol transport. And finally body weight sector represents dynamics of weight change and its effects on the blood cholesterol levels.



Figure 3.1 Interactions of Main Factors Affecting Blood Cholesterol Levels



Figure 3.2 Condensed Stock-Flow Diagram of the Main Variables

Time horizon of the model is in the neighborhood of a year and the time unit is one day. There may be significant variations in the values of the parameters within the time unit or a day, yet the model overlooks these dynamics and assumes average values instead. These average values are 12 hours fasting blood cholesterol levels, which could be seen in laboratory blood tests if administered.

There is not a direct feedback loop controlling the blood cholesterol level, yet other feedback loops or dynamics indirectly play with blood cholesterol levels to keep other critical stocks, namely the cholesterol pools in the liver and extrahepatic cells, within safe limits. If cholesterol in the liver becomes higher/lower than its normal level, then by decreasing/increasing its cholesterol uptake receptor activities, the liver adapts itself to take lesser/higher amounts of cholesterol from the blood. The effort of the liver, trying to stabilize its cholesterol pool, can be seen in more detail in Figure 3.3. A very similar feedback mechanism also exists in the extrahepatic cells. The details of this latter feedback

loop can be found in Figure 3.4. In all of the figures, HP and ET stand for hepatic and extrahepatic respectively.



Figure 3.3 Hepatic Cholesterol – HP Receptor Activity Causal Loop Diagram



Figure 3.4 Intracellular Cholesterol – ET Receptor Activity Causal Loop Diagram

Apart from the cholesterol pool feedback loops in the hepatic and extrahepatic cells, though indirect or user-intervened, other feedback loops can be defined through “diet - blood cholesterol – willingness to follow diet - diet”, and “exercise – good blood cholesterol (HDLC)- willingness to follow exercise - exercise”. Saturated fats increase both LDLC and HDLC whereas polyunsaturated fats increase HDLC, but decrease LDLC. The details of this discussion can be observed from the causal loop diagrams on Figure 3.5, Figure 3.6, Figure 3.7, and Figure 3.8. On the other hand exercise tends to increase HDLC, and decrease body weight after a delay, but becoming fatter decreases HDLC and increases LDLC. Having healthier HDLC, LDLC, and body weight levels tend people to have less willingness to pursue the exercise programs. Figure 3.9 summarizes this feedback or control mechanism.

These loops can be considered as user-intervened feedback loops, because people should adjust their actions, for example eating polyunsaturated fats or continuing exercise programs, if they observe changes in their cholesterol levels. These causal relationships can be regarded as control mechanisms rather than causal feedback loops, because there are exogenous factors involved like peoples’ awareness of rising cholesterol levels due to their diet, their willingness to take action to have lower cholesterol levels, and so on.

There are balancing/reinforcing loops between good blood cholesterol or HDLC and the nutritional ingredients that increase/decrease it. Also there exists similar, but not the same, causal relations between these nutrients and bad blood cholesterol or LDLC. Defining the causal relations simply as balancing or reinforcing loops might be rendered erroneous when the effect of weight change on blood cholesterols is taken into account. Weight change, which is a delayed response to the diet, may reverse the working direction of these loops in the long run. Also a particular nutritional ingredient can increase HDL and LDL, or increase HDL and decrease LDL. These relationships or feedback loops add to the complexity of the model even in the absence of the effect of weight change on blood cholesterol levels.



Figure 3.5 Saturated Fat – LDLC User-intervened Causal Loop Diagram



Figure 3.6 Polyunsaturated Fat – LDLC User-intervened Causal Loop Diagram



Figure 3.7 Saturated Fat – HDLC User-intervened Causal Loop Diagram



Figure 3.8 Polyunsaturated Fat – HDLC User-intervened Causal Loop Diagram



Figure 3.9 Exercise Loops

4. DESCRIPTION OF THE MODEL

4.1. Blood Sector

4.1.1. Background Information

VLDL is secreted from the liver for the purpose of transferring triacylglycerols to other tissues, mainly to the muscle and adipose tissue. After releasing most of its triacylglycerols, VLDL turns into intermediate density lipoprotein (IDL). Nearly half of IDL are taken up by the liver and extrahepatic tissues, whereas the other half is converted to low density lipoprotein (LDL). Thus the level of cholesterol bound to LDL (LDLC) is mainly from the cascading process of VLDLC turning into IDLC and finally to LDLC, where VLDLC and IDLC stand for the level of cholesterol bound to VLDL and IDL respectively. (Bhagavan, 2002; Murray, Granner, & Rodwell, 2006)

High density lipoproteins (HDL) are secreted from the steroidogenic tissues; mostly from the liver and the intestines. Main responsibility of HDL is to transfer cholesterol from extrahepatic cells to other lipoproteins, liver, and intestine. Movement of cholesteryl-ester to VLDL, IDL, and LDL is due to the activity of cholesteryl-ester transfer protein or CETP. Half of the cholesterol bound to HDLs (HDLC) is taken up by steroidogenic tissues while the other half goes to the other lipoproteins via the stimulation by CETP (Murray, Granner, & Rodwell, 2006; Packard, et al., 2000).

4.1.2. Fundamental Approach and Assumptions

In the model, for simplicity, steroidogenic tissues and their functions in the HDL metabolism are limited to liver. Also the liver is assumed to be maintaining a constant level of HDL productivity. CETP related cholesterol transfer is also assumed to be occurring only between HDL and VLDL, not taking IDL and LDL as receivers of cholesterol into account. Also any unmentioned factor that may affect lipoprotein metabolism in the blood is assumed to be constant or non-changing throughout the simulation horizon. These out-

of-boundary factors include metabolic syndromes, insulin related disorders, abnormal thyroid hormone levels, progression of liver diseases like fatty liver disease.

4.1.3. Description of the Blood Sector Structure

There are four stocks in this sector. *VLDLC*, *IDLC*, and *LDLC* have a relationship as a cascading process, while *HDLC* is related to these stocks via the flow *CETP Regulated C Transfer*. HDLC is short for cholesterol bound to HDL particles. HDLC has one inflow and two outflows. HDL cholesterol (HDLC) is increased with the HDL particles collecting cholesterol from extrahepatic tissues via SR-B1 regulated pathways or with other methods. This increase is represented with the inflow *Cholesterol Uptake by HDL* and analyzed in below in more detail. Because life of HDL particles is 4 days (Barter, Kastelein, Nunn, & Richard, 2003), cholesterol bound to the HDL particles are assumed to have the same clearance rate from the liver and this is modeled as *HDLC Transport to Liver* outflow in the model. The other outflow is *CETP Regulated C Transfer*. *CETP Activity Rate* converter in the model is short for the rate or speed of this CETP regulated transfer of cholesterol from HDL to VLDL particles. Because CETP regulated cholesterol transfer is nearly equal to the amount of cholesterol transferred to the liver by HDL (Kwiterovich, 2000), it should be equal to the reciprocal of the life of an HDL particle. So, it is equal to 0.25 day^{-1}. Also the initial level of HDLC is set to 31.5 mg/dL. The relationship of HDLC with its flows can be seen in the following equation. Complete set of equations can be found in Appendix A.

$$HDLC(t) = HDLC(t - dt) + (Cholesterol\ Uptake\ by\ HDL - HDLC\ Transport\ to\ Liver - CETP\ Regulated\ C\ Transfer) * dt \quad (4.1)$$

Cholesterol bound to VLDL (*VLDLC*) has two inflows and one outflow. Its first inflow is *VLDLC Secretion*. This inflow is the outflow of the *Hepatic Cholesterol Pool* stock which is located in the *liver section* and this flow is analyzed in the liver section in more detail. The normal value of this inflow is 128.6 mg/dL per day. The other inflow of *VLDLC* is *CETP Regulated C Transfer*. Cholesteryl ester transfer protein is responsible in the process of cleaving cholesterol form HDL particles and letting VLDL to capture these

cholesterols. Because *HDLC* is set to be 31.5 mg/dL at the beginning and *CETP Regulated C Transfer* equals to *HDLC * CETP Activity Rate*, then the normal value of this transfer equals to 31.5*0.25, or nearly 7.88 mg/dL per day. The outflow of *VLDLC* is *VLDL Turnover* and is equal to *VLDLC* times *VLDL Turnover Rate*. The latter rate is set to be 5.5 day^{-1} in the model (Packard, et al., 2000). VLDLC has the following defining relationship.

$$VLDLC(t) = VLDLC(t - dt) + (VLDLC\ Secretion + CETP\ Regulated\ C\ Transfer - VLDL\ Turnover) * dt \quad (4.2)$$

Cholesterol bound to IDL (*IDLC*) has one inflow, which is the only outflow of *VLDLC* just mentioned above, and three outflows. Two of the outflows are *Hepatic Uptake of IDL* and *Extrahepatic Uptake of IDL*. The first uptake is done by the liver receptors while the latter is done by the receptors of the extrahepatic cells. Nearly two thirds of the IDL are taken up by these pathways- 70% by liver and 30% by extrahepatic tissues (Murray, Granner, & Rodwell, 2006). Hepatic uptake equals to *IDLC*Effect of ET Receptor Activity on IDL Uptake*, and extrahepatic uptake equals to *IDLC*Effect of HP Receptor Activity on IDL Uptake*. More will be said about the receptor activities in the liver and extrahepatic tissues sections. The remaining cholesterol which is not taken up, or namely one third of IDLC, is degraded into *LDLC* which is represented by the *IDL Turnover* outflow. This outflow equals to *IDLC*IDL Turnover Rate*. *IDL Turnover Rate* is 2.4 day^{-1} (August, Parker, & Barahona, 2007), and the initial level of IDLC is set to 18.6 mg/dL. So the initial value of the *IDL Turnover Rate* is around 44.6 mg/dL per day. The formula of IDLC follows.

$$IDLC(t) = IDLC(t - dt) + (VLDL\ Turnover - IDL\ Turnover - Extrahepatic\ Uptake\ of\ IDL - Hepatic\ Uptake\ of\ IDL) * dt \quad (4.3)$$

IDL Turnover Rate is the only input of the stock *LDLC*, or cholesterol bound to LDL. *LDLC* also has three outflows: *Hepatic Uptake of LDL, Extrahepatic Uptake of LDL by Receptor Dependent Activity*, *Extrahepatic Uptake of LDL by Receptor Independent Activity*. LDLC is taken up by liver and extrahepatic tissues via both receptor dependent

and receptor independent activities. The first of the outflows *Hepatic Uptake of LDL* represents the degradation of LDL in liver. It equals to *LDLC * Effect of HP Receptor Activity on LDL Uptake + LDLC * Receptor Indep HP Uptake Rate*. These uptake rates are delineated in the liver section. The other outflows equal to *LDLC * Effect of ET Receptor Activity on LDL Uptake* and *LDLC * Receptor Indep ET Uptake Rate* respectively. The details of these uptake rates will be given in the extrahepatic tissue section. Initial values of LDLC and three outflows are about 111.5 mg/dL, 31.2 mg/dL per day, 10 mg/dL per day, 3.2 mg/dL per day respectively. The differential equation defining LDLC stock through time is the following.

$$LDLC(t) = LDLC(t - dt) + (IDL\ Turnover - Extrahepatic\ Uptake\ of\ LDL\ by\ Receptor\_Dependent\ Activity - Hepatic\ Uptake\ of\ LDL - Extrahepatic\ Uptake\ of\ LDL\ by\ Receptor\ Independent\ Activity) * dt \quad (4.4)$$

The person, whom blood cholesterol level is being modeled, is assumed to have cholesterol levels as borderline high. Initially HDLC, VLDLC, IDLC, and IDLC are set to 31.5, 25.0, 18.6, and 111.5 mg/dL respectively.

There are no feedback loops in this sector in isolation. The relationship between *VLDLC*, *IDLC*, and *LDLC* is merely a cascading process. Rather, other feedback loops, which will be modeled in the liver and extrahepatic tissue sectors, indirectly play with blood cholesterol levels to balance cholesterol pools in themselves. Stock - Flow diagram can be seen in Figure 4.1. Complete set of equations can be found in Appendix A.



Figure 4.1 Stock – Flow Diagram of Blood Sector

4.1.4. Dynamics of Blood Sector in Isolation

In this section, a number of tests will be conducted to verify that blood section works properly, i.e. it stays at or reaches a steady state. In order to verify the proper functioning of blood sector in isolation four experiments will be done. First, all of the variables will be initialized at their steady state values and the stocks will be checked to see if they stay at the equilibrium or not. Then as the second and third experiments, all of the stocks will be initialized at zero and then to an arbitrarily large number *500* respectively to see if they reach their equilibrium levels. Lastly the major inflows of the sector which are stemming from liver and extrahepatic sectors, *VLDLC Secretion* and *Cholesterol Uptake by HDL* will be given a normal noise of which's standard deviation equals to 20% of the original values to see the behavior of the system changes or not. All of the simulations will be run for 20 days. The parameter values in these experiments can be seen in the following table.

Table 4.1 Parameter Values in the Blood Experiments

				Experiment 4	
	Exp 1	Exp 2	Exp 3	Mean	St. Dev.
HDLC (mg/dL)	31.555	0.000	500.000	31.555	---
VLDLC (mg/dL)	25.000	0.000	500.000	25.000	---
IDLC (mg/dL)	18.575	0.000	500.000	18.575	---
LDLC (mg/dL)	111.450	0.000	500.000	111.450	---
VLDLC Secretion (mg/dL/day)	129.620	129.620	129.620	129.620	25.924
Cholesterol Uptake by HDL (mg/dL/day)	15.765	15.765	15.765	15.765	3.153

The results of the first three scenarios can be seen in Figure 4.2 through Figure 4.5. The first initial conditions seem to be equilibrium points, so that in the second and third experiments all of the stocks converge to these steady state values.



Figure 4.2 *HDLC* under Experiments 1, 2, and 3



Figure 4.3 *VLDLC* under Experiments 1, 2, and 3



Figure 4.4 *IDLC* under Experiments 1, 2, and 3



Figure 4.5 *LDLC* under Experiments 1, 2, and 3

After modifying the major inflows of the sector to have 20% of their mean values as their standard deviations, which can be seen in Table 4.1, the dynamic patterns of stocks does not seem to deviate to other points. They move randomly up and down around their equilibrium points as in the case of the first experiment. This behavior can be observed in the following graphs.



Figure 4.6 *HDLC* under Experiment 1 (HDLC 1), and Experiment 4 (HDLC 2)



Figure 4.7 *VLDLC* under Experiment 1 (VLDLC 1), and Experiment 4 (VLDLC 2)



Figure 4.8 *IDLC* under Experiment 1 (IDLC 1), and Experiment 4 (IDLC 2)



Figure 4.9 *LDLC* under Experiment 1 (LDLC 1), and Experiment 4 (LDLC 2)

4.2. Liver Sector

4.2.1. Background Information

Liver has vital roles in many bodily processes, as in the case of cholesterol metabolism. It directly and indirectly plays with blood cholesterol levels through HDL activity, VLDL cholesterol secretion, bile secretion, and hepatic receptor activities or uptake of cholesterol.

HDL is secreted from liver. It is responsible for the reverse cholesterol transport, which is the mechanism through which the excess cholesterol of extrahepatic tissues is transferred to liver and other blood lipoproteins.

Though VLDL is mainly produced for the purpose of transferring triacylglycerols to muscle and adipose tissue, some cholesterol is incorporated in them while they are secreted to the blood stream in liver. VLDL cholesterol secretion is dependent on hepatic cholesterol pool, some dietary nutrients, and body weight. Thus the origin of blood cholesterol level is mainly VLDL secretion and reverse cholesterol transport.

Lipids and cholesterol are not soluble in water. Bile is used to solve and uptake them in the digestive system. Bile and bile acids are secreted in the liver from cholesterol. Therefore their loss in the feces determines how much cholesterol in the liver will be utilized for new bile production. Because hepatic cholesterol pool determines the receptor dependent cholesterol uptake and VLDL-cholesterol secretion, bile metabolism is an indirect mechanism by which the liver plays with blood cholesterol levels.

The receptors are responsible for cholesterol uptake in the form of IDL cholesterol and LDL cholesterol. LDL cholesterol is also taken up by receptor independent activities by liver and extrahepatic tissues. Activities of the hepatic receptors are adjusted such that hepatic cholesterol pool does not exceed safe limits. If hepatic cholesterol pool is lower (higher) than its normal level, then hepatic receptor activity is increased (decreased) to allow more (less) cholesterol to be taken up from blood. This is another mechanism which involves liver and blood cholesterol interaction.

4.2.2. Fundamental Approach and Assumptions

Bile and bile acids are secreted and absorbed 4 to 10 times a day in the body, which is called enterohepatic circulation, and some portion of them is lost in the feces (Bhagavan, 2002). Bile loss and the compensation of this loss by the liver are modeled by using total daily values rather than treating every enterohepatic circulation individually. Because bile is accompanied with free cholesterol while it is secreted in the liver, some cholesterol, which amounts to be about 0.4 gr, is also lost to the feces (Guyton, et al., 1991). This loss is assumed to be compensated by the liver. Any other cholesterol use or loss, like structural use of cholesterol, is also assumed to be regulated by the liver. This compensation is to be represented with the flow *Hepatic Synthesis Control* in the model.

Moreover, receptor activity is assumed to be linearly correlated with the number of receptors in cell, which is between 15.000 and 75.000 (Goldstein & Brown, 1997).

4.2.3. Description of the Liver Sector Structure

There are two stocks in this section: *HP Receptor Activity* and *Hepatic Chol*. The first one represents the activeness or efficiency of liver receptors in taking up cholesterol from blood, while the second one represents the cholesterol amount in the liver.

HP Receptor Activity has only one bi-flow named *HP Receptor Adaptation*. If the *Hepatic Chol* pool is less (more) than its base level, then more (less) receptors are utilized in the liver surface. According to the ratio of hepatic cholesterol to its base level, HP Receptor Goal is calculated as follows.



Figure 4.10 HP Receptor Goal

If there is a lot of cholesterol in the liver, then the liver wants minimum of its receptors working which is a relatively low number, 15. And in the contrary, if the liver needs more cholesterol, the receptor goal increases to 75. The rationale behind these numbers 15 and 75 is the fact that a cell has between 15,000-75,000 LDL receptors (Goldstein & Brown, 1997), and the assumption that these numbers represent the receptor activity or efficiency of each cell and in turn liver. Normal level of receptors is assumed to be 60,000. Afterwards, the liver checks the surplus or need of the receptors by comparing the goal with the current level of the stock *HP Receptor Activity*. According to the resulting surplus or need the activity is decreased or increased. The adjustment time of this process is 2.5 days (Goldstein & Brown, 1997). Therefore the formula for *HP Receptor Adaptation* becomes:

$$\text{HP\_Receptor\_Adaptation} = \text{Receptor\_Surplus\_or\_Need\_in\_Liver} / \text{HP\_Receptor\_Adaptation\_Time} \quad (4.5)$$

The second stock of this sector is *Hepatic Chol*. It has two outflows, two inflows, and one bi-flow. Its outflows, inflows, and bi-flow are *VLDLC Secretion*, *Bile Secretion*; *Uptake from Blood*, *Chol from Diet*; and *Hepatic Synthesis Control* respectively. The

normal or base level *Hepatic Chol* is taken to be 1700 mg (Schwartz, Zech, VandenBroek, & Cooper, 1993).

VLDLC Secretion is the cholesterol loss rate in which cholesterol is bound to VLDL particles. This flow has a complicated formula which depends on the *Hepatic Chol* stock, saturated and unsaturated fat intake, and body weight. Its formula can be seen below.

$$\begin{aligned} VLDLC\_Secretion = {} & Base\_VLDLC\_Secretion \\ & *Effect\_of\_Hepatic\_Chol\_\_Pool\_on\_VLDLC\_Secretion \\ & -9.18+Effect\_of\_Saturated\_Fats\_on\_VLDLC\_Secretion \\ & *Absorbed\_\_Saturated\_Fats \\ & +12.97+Effect\_of\_Polyunsaturated\_Fats\_on\_VLDLC\_Secretion \\ & *Absorbed\_Polyunsaturated\_Fats \\ & +Effect\_of\_Body\_Weight\_on\_VLDLC\_Secretion \end{aligned} \tag{4.6}$$

The above effect formula is of multiplicative and additive form. *VLDLC Secretion* is affected by hepatic cholesterol level in a multiplicative way. Effects of saturated fats and polyunsaturated fats are introduced in an additive way. Base levels of these effects are 9.18 mg/dL and -12.97 mg/dL, therefore these constants are added to the formula in opposite sign. The details will be given in the digestive system and body weight sectors.

Base VLDLC Secretion is adjusted to be about 130 mg/dL a day in its normal or initial level (August, Parker, & Barahona, 2007). *Hepatic Chol* has effect on how much VLDL cholesterol is secreted from the liver. Therefore, base level secretion is multiplied with this effect in the formula above. The graphical function, which has the ratio of the stock to its base level or 1700 mg as its x-axis, can be seen in Figure 4.11.

The outflow *Bile Secretion* has an important role in cholesterol dynamics, but it will be analyzed in more detail in the digestive system sector.



Figure 4.11 Effect of Hepatic Cholesterol Pool on VLDLC Secretion

The bi-flow of *Hepatic Chol* is named as *Hepatic Synthesis Control*. As stated earlier the normal cholesterol pool level is taken to be 1700 mg. If the pool deviates from this level, the liver adjusts its production mechanisms so that cholesterol amount approaches the base level. If there is more cholesterol in the pool than that of the base level, then new cholesterol synthesis rate is reduced. The rate or speed of this process is assumed to be 0.5 days. Also, all of the other synthesis and usages of cholesterol in the liver and steroidogenic tissues are aggregated into this bi-flow. This flow has a constant 245 mg per day cholesterol input to the stock as a result of this aggregation.

Hepatic_Synthesis_Control = 245
+(Normal_Chol__Level_in_Liver-Hepatic_Chol)
/Hepatic_Synthesis_Control_Rate

(4.7)

Chol from Diet and *Uptake from Blood* are the inflows of the stock *Hepatic Chol*. *Chol from Diet* is merely the absorbed cholesterol from the diet. The latter represents the total receptor dependent uptake of cholesterol from IDL and LDL particles. *Uptake from Blood* also includes receptor independent cholesterol uptake from LDL particles.

Hepatic Uptake of IDL is *IDLC* times *Effect of HP Receptor Activity on IDL Uptake*. The effect formula is calculated as *HP Receptor Activity* times 0.0583, with the help of the paper (Packard, et al., 2000), after assuming that the effect is linear in HP Receptor Activity, and 70 per cent of the total IDL uptake from the blood occurs in liver (Goldstein & Brown, 1997; Murray, Granner, & Rodwell, 2006).

Hepatic Uptake of LDL includes receptor dependent and independent uptake of LDLC.

$$Hepatic\_Uptake\_of\_LDL = LDLC*Effect\_of\_HP\_Receptor\_Activity\_on\_LDL\_Uptake + LDLC*Receptor\_Indep\_HP\_Uptake\_Rate \quad (4.8)$$

After taking the same assumptions as in the case of IDL uptake, *Effect of HP Receptor Activity on LDL Uptake* equals to *HP Receptor Activity* times 0.0035 (Packard, et al., 2000). *Receptor Indep HP Uptake Rate* is taken to be 0.07 (Murray, Granner, & Rodwell, 2006; Dietschy, Turley, & Spady, 1993).

Stock - Flow diagram can be seen in Figure 4.12. Complete set of equations can be found in Appendix A.



Figure 4.12 Stock – Flow Diagram of Liver Sector

4.2.4. Dynamics of the Liver Sector in Isolation

As was the case for the blood sector, four experiments will be done. In the first test, the stocks of the liver sector will be initialized from their equilibrium levels: 1700 mg for *Hepatic Chol*, and 60 for *HP Receptor Activity*. In the second experiment, both of the stocks will be initialized from 0; and in the third one *Hepatic Chol* will be initialized from an arbitrarily high value 5000 mg and *HP Receptor Activity* from its maximum 75. The results for these three trials can be seen in Figure 4.13 and Figure 4.14. The parameter values can be seen in the following table.

Table 4.2 Parameter Values in the Liver Experiments

				Experiment 4	
	Exp 1	Exp 2	Exp 3	Mean	St. Dev.
Hepatic Chol (mg)	1700.00	0.00	5000.00	1700.00	---
HP Receptor Activity	60.00	0.00	75.00	60.00	---
HDLC Transport to Liver (mg/dL/day)	7.90	7.90	7.90	7.90	1.58
Hepatic Uptake of IDL (mg/dL/day)	65.00	65.00	65.00	65.00	13.00
Hepatic Uptake of LDL (mg/dL/day)	31.00	31.00	31.00	31.00	6.20
Bile Secretion (mg/day)	500.00	500.00	500.00	500.00	100.00
Chol from Diet (mg/day)	280.50	280.50	280.50	280.50	56.10
VLDLC Secretion (mg/dL/day)	130.00	130.00	130.00	130.00	26.00

Figure 4.13 *Hepatic Chol* under Experiments 1, 2, and 3

Figure 4.14 *HP Receptor Activity* under Experiments 1, 2, and 3

As expected, in the first experiment, the stocks remain at their initial levels if started at their equilibrium levels. In the second and third experiments, the stocks reach their equilibrium levels although in the third one HP Receptor Activity undershoots its stable level at first.

In the fourth experiment, major flows of the sector, which come or go to other sectors, are given normal noise. The mean of the noise is zero whereas the standard deviation of them equal to 20 % of the flows' own base levels. These flows are *HDLC Transport to Liver*, *Hepatic Uptake of IDL*, *Hepatic Uptake of LDL*, *Bile Secretion*, *Chol from Diet*, and *VLDLC Secretion*; and the values can be seen in Table 4.2. The results can be seen in the following figures.



Figure 4.15 *Hepatic Chol* under Experiment 1 (Hepatic Chol 1), and Experiment 4 (Hepatic Chol 2)

Figure 4.16 *HP Receptor Activity* under Experiment 1 (HP ReceptorActivity 1), and Experiment 4 (HP ReceptorActivity 2)

4.3. Extrahepatic Tissue Sector

4.3.1. Description of the Extrahepatic Tissue Sector Structure

Extrahepatic tissue represents all of the tissues or parts of the body that receive cholesterol from IDL and LDL; and give away cholesterol to HDL.

This sector is very similar to the liver sector. Some assumptions made in the liver sector are also made in this sector. These are using daily average values for the parameters, and assuming a linear relationship between receptor number and receptor activity. More information about these assumptions can be found in section 4.2.2.

Extrahepatic tissue sector has two stocks: *Intracellular Cholesterol* and *ET Receptor Activity*. The first represents the amount of cholesterol in the extrahepatic tissues, and the second represents the activeness or efficiency of the receptors in taking up cholesterol from blood. *Intracellular Cholesterol* has a base level of 1450 mg (Schwartz, Zech, VandenBroek, & Cooper, 1993).The same mechanisms and assumptions of *HP Receptor Activity* apply for *ET Receptor Activity*, and it has a base level of 60. It doesn't have a unit because it represents efficiency.

Intracellular Cholesterol has one inflow, two outflows, and one bi-flow. Its only inflow is cholesterol taken up from blood or *C from Blood*. It includes receptor dependent uptake of cholesterol from IDL and LDL particles together with receptor independent cholesterol uptake from LDL particles.

$$\begin{aligned} C\_from\_Blood = {} & Extrahepatic\_Uptake\_\_of\_IDL \\ & + Extrahepatic\_\_Uptake\_of\_LDL\_by\_Receptor\_Dependent\_Activity \\ & + Extrahepatic\_Uptake\_of\_LDL\_by\_Receptor\_Independent\_Activity \end{aligned} \tag{4.9}$$

Extrahepatic Uptake of IDL is *IDLC* times *Effect of ET Receptor Activity on IDL Uptake*. The effect formula is calculated as *ET Receptor Activity* times 0.025, with the same assumptions as in its hepatic counterpart (Packard, et al., 2000), namely assuming

that the effect is linear in ET Receptor Activity, and 30 per cent of the total IDL uptake from the blood occurs in extrahepatic tissues (Goldstein & Brown, 1997).

Extrahepatic Uptake of LDL includes receptor dependent and independent uptake of LDLC. *Extrahepatic Uptake of LDL by Receptor Dependent Activity* equals to *IDLC* times *Effect of ET Receptor Activity on LDL Uptake*. *Extrahepatic Uptake of LDL by Receptor Independent Activity* equals to *LDLC* times *Receptor Indep ET Uptake Rate*. After taking the same assumptions as in the case of IDL uptake, *Effect of ET Receptor Activity on LDL Uptake* equals to *ET Receptor Activity* times 0.0015. *Receptor Indep ET Uptake Rate* is taken to be 0.03 (Murray, Granner, & Rodwell, 2006; Packard, et al., 2000; August, Parker, & Barahona, 2007).

Cholesterol Uptake by HDL and *IC Cellular Usage* are the outflows of *Intracellular Cholesterol*. The first is the determining factor for the HDLC level in the blood. It is affected by dietary elements, body weight, and exercise. Its cumbersome formula is below. *Normal HDL Efficiency* represents the uptake that should be made in normal conditions. That means if all of the parameters that affect this flow are kept constant at their base levels in the model, then there would be no change in the value of the flow and it would be equal to this base or normal level which is set to be about 16 (August, Parker, & Barahona, 2007). *Normal HDLC Uptake Rate* represents the diminishing rate of HDL cholesterol in the blood which is 0.5 $days^{-1}$ (Barter, Kastelein, Nunn, & Richard, 2003). All of the effects are analyzed in more detail at their corresponding sections.

Cholesterol_Uptake_by_HDL = Normal_HDL_Efficiency+
(Effect_of_Body__Weight_on__HDLC_Efficiency+
-0.5633+Effect_of_Exercise_on_HDLC_Efficiency+
-5.25+Effect_of_Saturated_Fats_on_HDLC_Efficiency
**Absorbed__Saturated_Fats*
-5.50+Effect_of_Polyunsaturated_Fats_on_HDLC_Efficiency
**Absorbed_Polyunsaturated_Fats*
-5+Effect_of_Monounsaturated_Fats_on_HDLC_Efficiency
**Absorbed_Monounsaturated_Fats)*
**Normal_HDLC_Uptake_Rate*

(4.10)

Cholesterol is synthesized in virtually every living cell which has nucleus, yet cholesterol taken up from blood is a vital source. About 60 per cent of the cholesterol taken up from blood is used in cells (Aidels, 2002). Therefore in a given day, about 41 mg of cholesterol is taken up from blood, 25 mg of it is used in metabolic activities in the cell and about 16 mg is taken away by HDL. Assuming other cholesterol synthesis within the cells equal their usage throughout the simulation means their net effect is always zero. So in the beginning of the simulation the above 25 mg is taken to be *IC Cellular Usage* or the intracellular cholesterol used in the cell within a day. But this flow is also dependent on the relative level of the intracellular cholesterol to its base level in an assumed linear fashion. Therefore *IC Cellular Usage* equals to *Base IC Cellular Usage* times *Intracellular Cholesterol* divided by *Normal Chol Level in Extrahepatic Tissues*.

If there is a difference between intracellular cholesterol and its normal level 1450 mg, *Metabolic Chol Effect* bi-flow works to diminish this gap. A similar bi-flow is also present in the liver sector, but this one is assumed to have a rather slow speed, or *Metabolic Chol Effect Adjustment Time*, as 2 days compared to 0.5 days in its liver counterpart.

Stock - Flow diagram of this sector can be seen in Figure 4.17. Complete set of equations can be found in Appendix A.



Figure 4.17 Stock – Flow Diagram of Extrahepatic Tissue Sector

4.3.2. Dynamics of the Extrahepatic Tissue Sector in Isolation

The four-step experimental procedure is also used in this stock. Keeping all other stocks, flows, and auxiliary variables constant; stocks of this sector *Intracellular Cholesterol* and *ET Receptor Activity* will be initialized at their equilibrium values in the first experiment. In the second one, these stocks will be 0 at the start of the simulation. In the third experiment, *Intracellular Cholesterol* will be initialized from an arbitrarily high value 5000 mg and *ET Receptor Activity* from its maximum 75. The parameter values in these tests can be seen in the table below. The results can be seen in the following figures.

Table 4.3 Parameter Values in the Extrahepatic Tissue Experiments

				Experiment 4	
	Exp 1	Exp 2	Exp 3	Mean	St. Dev.
Intracellular Cholesterol (mg)	1450.00	0.00	5000.00	1450.00	---
ET Receptor Activity	60.00	0.00	75.00	60.00	---
C from Blood (mg/dL/day)	41.00	41.00	41.00	41.00	8.20
IC Cellular Usage (mg/day)	25.46	25.46	25.46	25.46	5.09
Cholesterol Uptake by HDL (mg/dL/day)	16.00	16.00	16.00	16.00	3.20



Figure 4.18 *Intracellular Cholesterol* under Experiments 1, 2, and 3

Figure 4.19 *ET Receptor Activity* under Experiments 1, 2, and 3

In the fourth and last experiment for this sector, major flows, which are exogenous to the sector, are given normal noise. The mean of the noise is zero whereas the standard deviation of them equal to 20 % of the flows' own base levels. These flows are *C from Blood, IC Cellular Usage,* and *Cholesterol Uptake by HDL* and these values can be seen in Table 4.3. The results, which can be seen in the following figures, suggest that the intracellular cholesterol pool, which is vital for many bodily processes, is robust to the fluctuations in the changed flows. The values of the stocks in this sector are not significantly changed with changes in the values of *C from Blood, IC Cellular Usage,* and *Cholesterol Uptake by HDL*.



Figure 4.20 *Intracellular Cholesterol* under Experiment 1 (Intracellular Cholesterol 1), and Experiment 4 (Intracellular Cholesterol 2)



Figure 4.21 *ET Receptor Activity* under Experiment 1 (ET Receptor Activity 1), and Experiment 4 (ET Receptor Activity 2)

4.4. Digestive System Sector

4.4.1. Background Information

Digestive system has important roles in cholesterol balance in the body. Bile salts are used in the absorption of fats and cholesterol from the diet. These dietary nutrients are among the determining factors of blood cholesterol levels. Moreover, bile and bile salts are produced from cholesterol in the liver and most of them are recycled to the liver from the intestines. This is called enterohepatic circulation. The loss of bile from the intestines, thus, affects how much new bile will be produced and, though indirectly, how much cholesterol will be taken up from blood (Stein & Stein, 1999; Tall, 1990).

Absorbed cholesterol indirectly plays with blood cholesterol levels. It increases the cholesterol pool in the liver and causes hepatic receptor activity to decrease which in turn causes blood cholesterol levels to rise.

Dietary fats increase HDL cholesterol. Saturated fats increase, polyunsaturated fats decrease, and monounsaturated fats do not affect LDL cholesterol (Hegsted, Ausman, Johnson, & Dalla, 1993).

High fibers in the diet promote bile loss in the feces. Loss in the absorption of bile and bile salts mean lesser absorption of cholesterol and dietary fats in the diet (Cohen, 2007).

4.4.2. Fundamental Approach and Assumptions

Time unit in the model is one day. But, bile secretion for example, is done 4-10 times a day. What is modeled in the study is not this individual event; it's rather an accumulation or aggregation of events that occur in one day. Thus *Bile Secretion* in the model represents all of the new bile produced and *Bile Loss in Feces* represents the total amount of bile lost in feces throughout a day. Bile is actually accompanied by cholesterol in bile's journey from liver to intestines, and some cholesterol is also lost in feces (Cohen, 2007). This cholesterol loss is assumed, and actually is, compensated by the production in liver or the cholesterol pool therein and is not modeled in the study.

Studies about the effect of dietary elements on LDL and HDL cholesterol are generally regression studies (Hegsted, Ausman, Johnson, & Dalla, 1993; Mensink, Zock, Kester, & Katan, 2003). Therefore the effects are taken to be linear and additive in the study.

4.4.3. Description of the Digestive System Structure

The only stock in this sector is *Bile Chol*. Its normal or base level is 3000 mg (Cohen, 2007). Its inflow is *Bile Secretion* and outflow is *Bile Loss in Feces*. The latter flow is taken to have a base level of 500 mg a day (Bhagavan, 2002; Cohen, 2007). This base level is affected by dietary high fibers so that *Bile Loss in Feces* equals to *Base Bile Loss Rate* multiplied by *Effect of High Fibers on Bile Loss*. High fibers cause less bile to be absorbed in the intestines. So they increase bile loss in feces. Their contribution to lower blood cholesterol is about 5 per cent (Citkowitz, 2007). So the graphical function *Effect of High*

Fibers on Bile Loss is adjusted to cause this level of change in blood cholesterol level. The following figure shows this effect formula in detail.



Figure 4.22 *Effect of High Fibers on Bile Loss*

Bile is strictly monitored in the liver and intestines and the liver takes action to return the bile pool to its normal level accordingly. Normal Bile Secretion equals to normal bile loss level which is 500 mg. *Bile Discrepancy* is defined to be normal level of bile minus the current level of bile, or *Normal Bile - Bile_Chol*. Also *Hepatic Chol*, the cholesterol stock in the liver, has control over how much new bile will be produced from cholesterol in the liver. So the formula for *Bile Secretion* is:

$$\textit{Bile Secretion} = \textit{Normal Bile Secretion} * \textit{Effect of Hepatic Chol on Bile Secretion} + \textit{Bile Discrepancy} / \textit{Bile Adjustment Time} \quad (4.11)$$

Effect of Hepatic Chol on Bile Secretion can be seen in Figure 4.23.

Normal Cholesterol Absorption Ratio is 0.55. *Absorbed Cholesterol* is also assumed to be affected by the level of bile in the sector. So the formula for *Absorbed Cholesterol* is *Cholesterol Intake * Normal Cholesterol Absorption Ratio * Effect of Bile on Cholesterol Absorption per cent*. The latter effect formulation is assumed to be equal to *Bile_Chol* /

Normal Bile. *Absorbed Cholesterol* is an inflow to the hepatic cholesterol pool, which is discussed in the liver sector in detail.

Fat Absorption per cent is affected from the level of bile. The normal absorption of fats is about 95 per cent. Figure 4.24 depicts the details of the parameter *Fat Absorption per cent*. The absorbed saturated, monounsaturated, and polyunsaturated fats are defined to be the multiplication of *Fat Absorption per cent* with their corresponding dietary intakes.

Base levels of carbohydrate and protein absorption are taken to be 99 and 90 per cent respectively. They are assumed to be constant throughout the simulation. *Absorbed Carbohydrates* and *Absorbed Proteins* are defined to be equal to these per cent values of the corresponding caloric intakes of the nutrients.



Figure 4.23 *Effect of Hepatic Chol on Bile Secretion*



Figure 4.24 *Fat Absorption per cent*

1 gr of fat has 9 kcal, whereas 1 gr of carbohydrate and protein has 4 kcal. Of all the available dietary calories, 10 per cent is lost in the processes of digestion mainly in the intestines and it is called *Thermic Effect of Food*. *Total Available Dietary Energy* is thus equals to:

Total Available Dietary Energy = ((Absorbed Polyunsaturated Fats
+Absorbed Saturated Fats
+Absorbed Monounsaturated Fats)
**energy per gr fat*
+Absorbed Carbohydrates
**energy per gr carbodydrate*
*+Absorbed Proteins*energy per gr protein)*
**(1-Thermic Effect per cent of Foods)*

(4.12)

Effects of dietary nutrients on LDL and HDL cholesterol levels are calculated from the information given on (Hegsted, Ausman, Johnson, & Dalla, 1993) and (Mensink, Zock, Kester, & Katan, 2003). *Effect of Saturated Fats on VLDLC Secretion* equals to 0.774 (cholesterol mg) / (fat gr). *Effect of Polyunsaturated Fats on VLDLC Secretion* equals to 0.546 (cholesterol mg) / (fat gr). *Effect of Saturated Fats on HDLC Efficiency* equals to

0.442. *Effect of Polyunsaturated Fats on HDLC Efficiency* equals to 0.232. *Effect of Monounsaturated Fats on HDLC Efficiency* equals to 0.105.

The incorporation of these effect formulations into the flow formulas are adjusted such that the normal or initial amount of dietary intakes does not affect the level of the flows. For example, *Effect of Saturated Fats on VLDLC Secretion* equals to 0.774 (cholesterol mg) / (fat gr) in the model. This effect appears in the formulation of *VLDLC Secretion* as: *VLDLC Secretion = Base VLDLC Secretion ... -9.18 + Effect of Saturated Fats on VLDLC Secretion * Absorbed Saturated Fats*. The number *-9.18* is chosen such that Absorbed Saturated Fats (11.875 gr) times the effect (0.774 mg / gr) is equal to 9.18 and the net effect in the base level of the parameters is zero.

Stock - Flow diagram of this sector can be seen in Figure 4.25. Complete set of equations can be found in Appendix A.



Figure 4.25 Stock– Flow Diagram of Digestive System Sector

4.5. Body Weight Sector

4.5.1. Background Information

Body weight dynamics are well studied in the literature. There are also simulation and system dynamics studies trying to explain the balance of body weight which is affected by energy intake and physical activities (Abdel-Hamid, 2002; Westerterp, Donkers, Fredrix, & Boekhoudt, 1994).

In the widely shared mental model, it is transparent enough that if daily energy intake is more (less) than daily energy expenditure, then daily energy surplus (deficit) causes body mass to increase (decrease) (Whitney & Rolfes, 1999)

Energy expenditure can be divided into three. Resting energy expenditure is defined as the energy need of an individual who is awake and at rest. This component is the biggest of all the energy expenditure components in a sedentary individual (Abdel-Hamid, 2002). The second one is energy used for muscular activities or thermic effect of exercise. The last one is thermic effect of food which is mentioned in the digestive system sector.

Body gains weight mainly in the form of fat or adipose tissue independent of the form of dietary components: fat, carbohydrates, or proteins. There are about 7716 kcal in human fat. Therefore, 7716 kcal of deficit in energy balance is considered to be causing 1 kg of body weight loss. The assumption in this estimate is that, energy need of the body remains stable even when the body weight changes (Weinsier, Bracco, & Schultz, 1993). Also another simplification is that body weight is assumed to be lost entirely from the adipose tissue. It is possible to divide body mass into two: fat mass, and fat-free mass. These two have different weight change characteristics; and respond to diet and exercise differently. Therefore observed weight loss or gain in real life is actually less than expected from the 7716 kcal – 1 kg estimate.

4.5.2. Fundamental Approach and Assumptions

The complexity in body weight change dynamics is represented in the model via taking the viewpoint of the paper *Energy intake, physical activity and body weight: a simulation model* (Westerterp, Donkers, Fredrix, & Boekhoudt, 1994). First it is assumed that if there is an energy surplus that is going to be converted to body mass, there is a cost in converting these nutrients to fat. Secondly, if there is energy deficit, then basal metabolism is reduced by 10 per cent by the body for the purpose of not losing its energy deposits rapidly.

Moreover, basal metabolism is changed with the body weight. In the normal range of weight values, it is assumed that weight change is linear as in the case of the basal metabolism approximation formulation of Friedervald's. It is assumed that when the body weight increases to 40 per cent above its normal level, basal metabolism increases more than that would increase in the linear case. Also when the body weight drops to about 80 per cent of its base level, basal metabolism decreases more than it would be in the Friedervald's formulation to not lose more weight or energy deposits.

Also for the sake of simplicity, body mass is not divided into two components. Fat mass and fat-free mass are assumed to be represented by *Body Weight* stock in the model.

4.5.3. Description of the Body Weight Sector Structure

The mentioned conceptual model is used with the added complexities with the help of the paper *energy intake, physical activity and body weight* and the Fiedervald's method (Westerterp, Donkers, Fredrix, & Boekhoudt, 1994). As explained in the digestive system sector, *Total Available Dietary Energy* is the calories taken from the blood minus the thermic effect of food. *Total Energy Need* is defined as *Basal Metabolism* plus *Exercise and Normal Activities*. The difference between them is *Energy Surplus or Shortage*. If there is energy surplus, the cost of converting nutrients to adipose tissue is added to this auxiliary variable. This cost is represented in the model as the graphical formulation *Effect of Fat Conversion to Energy balance*. Its details can be seen in Figure 4.26.



Figure 4.26 *Effect of Fat Conversion to Energy balance*

There are two stocks in the model. The first is *Body Weight* and the second is *Basal Metabolism*. *Body Weight* has one bi-flow. *Energy Surplus or Shortage* is used for calculating *Weight Change*.

$$\begin{aligned} \textit{Weight Change} = {} & \textit{Energy Surplus or Shortage} \\ & / \textit{Adjustment Time for Weight Change} \\ & / \textit{energy kg convertor} \end{aligned} \tag{4.13}$$

Adjustment Time for Weight Change is taken to be 1 day, and *energy kg converter* as 7716 kcal per gr. Base and initial *Body Weight* is taken to be 74 kg.

The other stock *Basal Metabolism* also has one bi-flow. It's named as *BM Change*. It's formulated as:

$$\begin{aligned} \textit{BM Change} = {} & \textit{(Base Basal Metabolism} * \textit{Effect of Body Weight on Basal Metabolism} \\ & \textit{-Basal Metabolism)/BM Change Rate} \\ & +\textit{Metabolic Adjustment Effect} \end{aligned} \tag{4.14}$$

Base Basal Metabolism and the initial level of the stock is set to 1800 kcal. But this level depends on the body weight as described in the above sections. *Effect of Body Weight on Basal Metabolism* is defined as:



Figure 4.27 *Effect of Body Weight on Basal Metabolism*

BM Change Rate is set to 0.5, assuming the speed of change in *Basal Metabolism* is 0.5 days. Metabolic Adjustment Effect represents the body's effort of reducing basal metabolism by 10 per cent if there is energy shortage in a given day.

Body weight has effect on LDL and HDL cholesterol levels. Its effect on LDL is modeled as an adjustment in the production of VLDL cholesterol or VLDLC. *Effect of Body Weight on VLDLC Secretion* is formulated as (*Body Weight-Base Body Weight) * 1.95* (Dattilo & Kris-Etherton, 1992). Its effect on HDL cholesterol level is represented with *Effect of Body Weight on HDLC Efficiency*. It's defined as: (*Body Weight-Base Body Weight) * 0.351*.

Stock - Flow diagram of this sector can be seen in Figure 4.28. Complete set of equations can be found in Appendix A.



Figure 4.28 Stock– Flow Diagram of Body Weight Sector

4.5.4. Dynamics of the Body Weight Sector in Isolation

For comparing the dynamics of this sector with literature, three experiments will be made. In the first experiment, the behavior of the model is compared with the real data appeared on Heyman *et al* (1992) in which the subject has reduced caloric intake for 21 days. In the second experiment, the subjects are overfed for 42 days. Lastly in the third one the results of the experiment will be compared with the results of the simulation model developed by Westerterp *et al (1993)*.

4.5.4.1. Short Term Weight Loss In the work of Heyman et al, the mean weight of the seven men is 69.2 kg. Their mean energy intake, in no weight change situation or at equilibrium, is 15.3 MJ/d or 3657 kcal/d. After taking out the cost of Thermic Effect of Food, this is about 10 per cent of the energy intake; Total Available Dietary Energy becomes 3290 kcal. At equilibrium this must be the total of Basal Metabolism and Exercise and Normal Activities. They are set to 3000 kcal and 290 kcal respectively.

In the study, the subjects had 730 kcal/d less energy intakes, and this value took *Thermic Effect of Food* into account. As a result, the subjects lost 2.00 kg in 21 days. This value is simulated to be 2.35 kg in the simulation. The following figure depicts the situation in which the subject's diet is reduced by 730 kcal per day after day 3.



Figure 4.29 Simulation vs. Real Data – Heyman *et al*

It is reasonable to state that the model generates an adequate result which is comparable to the mean of the subjects' body weight dynamics.

4.5.4.2. Short Term Weight Gain: Diaz *et al* overfed his 9 male subjects whose base basal metabolism and exercise level was 2715 kcal per day, and body weight as 73.4 kg. The experiment was run for 42 days. In the experiment, caloric intake is increased such that total available dietary energy rose to 4000 kcal per day. In the end of the 42 day period, the subjects, on the average, gained 7 kg or their mean body weight became 80.4 kg.

After adjusting the initial levels of the stocks and parameters to the levels implied above, the body weight increased to 84.17 kg. The result can be seen in Figure 4.30.

Figure 4.30 Simulation vs. Real Data – Diaz *et al*

4.5.4.3. Long Term Weight Loss In this experiment, the simulation results for a weight loss scenario for 26 weeks and 52 weeks will be compared with the results of the model prepared by Westerterp *et al* (1994). In this scenario, a 75 kg male has a total energy expenditure of 3100 kcal a day, which equals to basal metabolism plus exercise and normal activities. The energy intake of the subject is reduced by 430 kcal per day for 52 weeks.

These parameters are loaded to the model and it is run for 52 weeks or for a year. The model of Westerterp shows the subjects body weight as 68.6 kg and 64.4 kg in 26 weeks and 52 weeks respectively. These values are close to the values found in this study which are 68.7 kg and 66.3 kg. These results can be seen in Figure 4.31.



Figure 4.31 Simulation vs. Westerterp *et al* results

4.6. Diet and Exercise Sector

This sector mainly comprises from external variables which are related to diet and exercise as the name of this sector implies. At the base level the person is assumed to be doing 150 kcal of exercise and daily activities each day so that he has a sedentary life style. There is one graphical function that represents the effect of exercise on HDL cholesterol. *Effect of Exercise on HDLC Efficiency* is defined as in Figure 4.32 (Trejo-Gutierrez & Fletcher, 2007).



Figure 4.32 *Effect of Exercise on HDLC Efficiency*

Converters about diet and their base levels in parentheses are: Cholesterol Intake (510 mg/d), Saturated Fat Intake (12.5 gr/d), Monounsaturated Fat Intake (50 gr/d), Polyunsaturated Fat Intake (25 gr/d), Carbohydrate Intake (281.25 gr/d), Protein Intake (84.375 gr/d), High Fibers (10 gr/d), and Base Level of High Fibers (10 gr/d).

Transfats and simple carbohydrates are not modeled separately. They are assumed to be constant, or zero, in the base run and all of the scenarios.

5. BASE BEHAVIOR OF THE WHOLE MODEL AND VALIDITY TESTS

5.1. Base Run

The patient has borderline high blood cholesterol values. He weighs 74 kg. If he keeps his diet and exercise constant he gets the same blood levels throughout time and a total to HDL cholesterol ratio of 5.9. Since this ratio is quite high, he should consider some ways to lower his total cholesterol level and this ratio. His base level of VLDLC, IDLC, LDLC, and HDLC are 25 mg/dL, 18.57 mg/dL, 111.45 mg/dL, and 31.56 mg/dL. His total blood cholesterol is 186.5 mg/dL. As seen in the Figures 5.1 to 5.3 all of the stocks stay in their equilibrium levels if initialized there.



Figure 5.1 Base Equilibrium Run – Blood Cholesterol Levels



Figure 5.2 Base Equilibrium Run – Body Weight, Total Cholesterol and Cholesterol Ratio



Figure 5.3 Base Equilibrium Run - Cholesterol Pools, Receptor Activities and Bile

In this part, letting some inputs and parameters in the model have random values is employed to test the reference dynamics of the model disturbed by randomness. For this purpose the following parameters are set to have 20% of their mean values as their standard deviations: *High Fibers*, *Cholesterol Intake*, *Saturated Fat Intake*, *Polyunsaturated Fat Intake*, *Monounsaturated Fat Intake*, *Carbohydrate Intake*, *Protein Intake*, *Exercise and Normal Activities*, *Normal Bile Secretion*, *Base VLDLC Secretion*, *Hepatic Synthesis Control Rate*, *HDL Removal Time*, *Normal HDL Efficiency*, *CETP Activity Rate*. The parameter values can be seen in the following table.

Table 5.1 Parameter Values in the Stochastic Version of the Model

	Base Run	Random Experiment	
	Value	Mean	St. Dev.
High Fibers (gr/day)	10.00	10.00	2.00
Cholesterol Intake (mg/day)	510.00	510.00	102.00
Saturated Fat Intake (gr/day)	12.50	12.50	2.50
Polyunsaturated Fat Intake (gr/day)	25.00	25.00	5.00
Monounsaturated Fat Intake (gr/day)	50.00	50.00	10.00
Carbohydrate Intake (gr/day)	281.25	281.25	56.25
Protein Intake (gr/day)	84.38	84.38	16.88
Exercise and Normal Activities (kcal/day)	150.00	150.00	30.00
Normal Bile Secretion (mg/day)	500.00	500.00	100.00
Base VLDLC Secretion (mg/dL/day)	129.62	129.62	25.92
Hepatic Synthesis Control Rate (1/day)	0.50	0.50	0.10
HDL Removal Time (day)	4.00	4.00	0.80
Normal HDL Efficiency (unitless)	15.78	15.78	3.16
CETP Activity Rate (unitless)	0.25	0.25	0.05

The important measures for the whole model, Total Cholesterol and Total Cholesterol to HDLC Ratio can be seen in the following figures. We see from these figures that randomness in the above model parameters result in stable oscillations around the equilibrium levels, as would be expected in real life.



Figure 5.4 Total Cholesterol Under Base Run and Random Experiments



Figure 5.5 Total Cholesterol to HDLC Ratio Under Base Run and Random Experiments

5.2. Behavior Validity Tests

Sector-wise validity checks were made in the earlier blood, liver, extrahepatic tissues, and body weight sectors. In this section, the paper by Burke *et al* (2006) is used as a reference point to check the validity of the whole model. In the study 84 subjects were used and their dietary intakes were changed such that they had less calories and fat. The experiment was done for 6 months.

Base and equilibrium levels of the model are modified such that the characteristics of these subjects are represented in the model. The mean and standard deviation, (mean, standard deviation) of the parameters and initial values in the real case are: body weight (94.4, 14.23 kg), total cholesterol (206.31, 41.3 mg/dL), HDLC (52.26, 12.1 mg/dL), and LDLC (127.53, 36.7 mg/dL).

Before the experiment, the subjects' diet had (2023.76, 660.66 kcal). This intake was reduced to (1487.78, 475.23 kcal). Also the fat percentage of the diet is reduced: saturated fat from (11.96, 3.27) to (8.20, 3.53), monounsaturated fat from (13.42, 2.94) to (9.23, 3.54), and polyunsaturated fat from (7.20, 2.21) to (6.22, 2.30). Carbohydrate percentage of the diet is increased from (50.31, 7.72) to (61.37, 9.25). Protein percentage remains fairly the same (15.15, 3.41) at first, and (15.07, 3.46) in the experiment. All of the values are in the form (mean, standard deviation).

In simulation, the mean of the above parameters are used and the equilibrium levels of the stocks are set to be equal to real case counterparts by changing some flows from their base levels. All of the parameters and equations can be seen in Appendix B. The equilibrium levels can be seen in Figure 5.6, and Figure 5.7.



Figure 5.6 Validity Run Equilibria – Blood Cholesterol Levels



Figure 5.7 Validity Run Equilibria – Body Weight, and Total Cholesterol

At time 10, all of the dietary parameters are decreased to the mean levels stated above and simulated for another 6 months or 180 days as in the real experiment. The dynamics can be seen in the following two figures.



Figure 5.8 Validity Run Experiment – Blood Cholesterol Levels



Figure 5.9 Validity Run Experiment – Body Weight, and Total Cholesterol

The starting body weight was 94.40 kg in the simulation and this value also was the average body weight in the real case. In the real case, body weight is reported to decrease to (86.90, 15.55 kg), while in the simulation it became 89.44 kg. In the real case total cholesterol decreased to (197.73, 39 mg/dL) from its average value 206.42 mg/dL. In the simulation it decreased to 179.05 mg/dL from 206.42 mg/dL. The reported LDLC in the paper is (121.29, 33.54 mg/dL), whereas in the simulation (LDLC + IDLC) it is 111.88 mg/dl. The base level in both cases is about 130 mg/dL. HDLC is reported to decline little

compared to other factors: it decreased by 1.56 mg/dL with a standard deviation of 7.41 mg/dL. HDLC decreased by 7.1 mg/dL in the simulation.

The reported values have high standard deviations. This may not be due to random error since the number of subjects is 84 and it's fairly a high number for such a costly experiment. (There are lots of similar experiments with less than 20 participants in the literature that are not considered for benchmarking the model's performance). The high variations may be due to the nonlinearities in control parameters, or uncontrolled/ unobserved situations like the stress level of the subjects, deviations from the controlled diets, decreasing level of exercise, smoking, gender etc… The most contributing factor for the uncertainty in the response variables like total body weight, and total blood cholesterol is probably due to genetics of the people. Different people respond differently to changing factors like the body weight and diet. The amount of reaction may differ in body weight (Mensink, Zock, Kester, & Katan, 2003), whereas the reaction to some dietary elements like monounsaturated fats may even be positive in some people while negative in the others (Dattilo & Kris-Etherton, 1992).

Though there are variations in the response variables in the real case with possible reasons stated above, the simulation model predicts the behavior in the correct direction and in reasonable valid ranges. The response values are estimated within from 0.3 standard deviation error (LDLC), to one standard variation error (HDLC). Taking everything into consideration due to the different genetics of people, it is impossible to build a model that predicts the cholesterol dynamics of each person point-by-point, yet a model can be designed and calibrated such that it represents the cholesterol dynamics of "a specific" person adequately. Such a specific calibration is not the purpose of this thesis, nor do we have access to any such individual experimental data. We suggest such a study as a further research topic. We can nevertheless state based on the validity dynamics shown above that our model can capture the fundamental dynamics and levels of the main cholesterol variables adequately.

6. SCENARIO ANALYSIS

6.1. Normal Subjects

Since the normal subject has borderline blood cholesterol levels, he should try to find ways to lower them. In the first experiment, he will add hazelnuts to his diet, which are argued to decrease blood cholesterol levels, without any change in his lifestyle. In the second scenario, he compensates the extra calories from hazelnut by reducing his carbohydrate intake. In the third and fourth scenarios he tries to lose weight firstly by reducing his dietary intake and secondly by increasing the amount of exercise. In the fifth and last experiment of the normal subjects, he does more exercise but compensated all of his lost calories by eating more such that he has constant body weight.

6.1.1. 50 gr Hazelnut a day

The subject eats a handful, or 25 gr, of nuts a day. 25 gr of hazelnut contains: 4.25 gr carbohydrates, 2.5 gr dietary fiber, 1 gr saturated fat, 11.5 gr monounsaturated fat, 2 gr polyunsaturated fat, 3.75 gr protein.

If he starts to add 25 gr of hazelnut to his diet, does not change any other practice in his life, and considers only the first month of his changed diet, he should think that adding hazelnuts really works. This can be seen in Figure 6.1 and Figure 6.2.

His total cholesterol decreased to 185 mg/dL from 186.6 mg/dL. There is also a slight decrease, 3.2 mg/dL, in LDLC; and 0.5 mg/dL decrease in IDLC. But, HDLC increased by 1.81 mg/dL. This caused his total to HDL cholesterol ratio to decrease to 5.5 from 5.9. But within this first month he gained nearly a half kg, and he should bear his mind that body weight has effect on LDLC and HDLC. To see the long term dynamics, the model is run till day 2000. The results can be seen in Figure 6.3 and Figure 6.4.



Figure 6.1 Hazelnuts First Month – Blood Cholesterol Levels



Figure 6.2 Hazelnuts First Month – Body Weight, Total Cholesterol and Cholesterol Ratio

His *total cholesterol* was better for about 2.5 months, while his *total to HDL cholesterol ratio* was less than normal, meaning better, for about 8 months. But, as said before, he should keep in mind that he is gaining weight. He only gains about 4 kg at the time his ratio was back to 5.9, though he had seen 5.5 in his first month after starting to eat hazelnuts! At the end of the simulation he gains a total of 10 kgs, and his has *total cholesterol* and his *total to HDL cholesterol ratio* rises to 202 mg/dL and 6.8, from 186.6 mg/dL and 5.9 respectively. Therefore, in the short run this diet is healthful but in the long run it deteriorates his health.



Figure 6.3 Hazelnuts 2000 days – Blood Cholesterol Levels

Figure 6.4 Hazelnuts 2000 days – Body Weight, Total Cholesterol and Cholesterol Ratio

6.1.2. More Hazelnut, Less Carbohydrates - Unchanged caloric Intake

If he had thought that hazelnuts, even it's 25 gr, has some potential to gain weight, he should have taken less carbohydrates to compensate those calories added by the hazelnut. So he should cut about 40 gr of carbohydrates not to gain weight. As seen in Figure 6.5 and

Figure 6.6, his body weight stays constant at 74 kg and his total cholesterol decreased to 184 mg/dL from 186.6 mg/dL. There is a 3.9 mg/dL reduction in LDLC; and 0.4 mg/dL decrease in IDLC. But, HDLC increased by 2.0 mg/dL. This caused his total to HDL cholesterol ratio to decrease to 5.5 from 5.9. Therefore, in this scenario hazelnut recipe works in the short and long run, because body weight does not change throughout the simulation.



Figure 6.5 Isocaloric Case – Blood Cholesterol Levels

Figure 6.6 Isocaloric Case – Body Weight, Total Cholesterol and Cholesterol Ratio

6.1.3. Weight Loss

In this case he will have a 150 kcal deficit in his energy balance via either reduced dietary intake, or increased exercise.

6.1.3.1. Reduced Dietary Intake In this case he cuts fats, carbohydrates, and proteins proportionally. All of the ingredients in his diet are decreased by 7.67 per cent to make a total of 150 kcal energy reduction. Because of the assumed proportionality, his dietary fibers and dietary cholesterol are also lowered by 7.67 per cent.

He starts his new diet at day 10. In the first two months he does not see much improvement in his body weight and blood cholesterol levels as seen in Figure 6.7 and Figure 6.8.



Figure 6.7 Reduced Dietary Intake – Blood Cholesterol Levels



Figure 6.8 Reduced Dietary Intake- Body Weight, Total Cholesterol and Cholesterol Ratio

In the long run, he sees improvements in his blood cholesterol levels and body weight. There is a sharper decrease in HDLC than LDLC, so at first his *total to HDL cholesterol ratio* increases. But, as he begins to lose weight, his HDLC increases while his LDLC increases and this ratio begins to decrease. At the end of the simulation, he loses about 6 kg, his total to HDLC ratio decreases to 5.35 from 5.9, and his total cholesterol decreases to 173.5 mg/dL from 186.6 mg/dL, whereas his HDLC level increases to 32.4 mg/dL from 31.5 mg/dL. These results can be seen in the following figures. Also the initial reduction in the level of HDL cholesterol is reported on the literature as the decrease in HDLC in the period of actively losing weight (Dattilo & Kris-Etherton, 1992). This reduction is also seen in the simulation, but it is due to the reduced intake of fats. If fat content of the diet was not reduced than this initial reduction should not be observed.



Figure 6.9 Reduced Diet – Blood Cholesterol Levels

Figure 6.10 Reduced Diet - Body Weight, Total Cholesterol and Cholesterol Ratio

6.1.3.2. Increased Exercise In this scenario, he increases his daily activities by practicing more to burn 150 more kcal per day. This can be done by having a 30 minutes of fast paced walk, 20 minutes of biking, or 15 minutes of playing soccer. The results follow:



Figure 6.11 Increased Exercise - Blood Cholesterol Levels



Figure 6.12 Increased Exercise - Body Weight, Total Cholesterol and Cholesterol Ratio

In the first 10 days of the exercise, there is a sharp change in the blood cholesterol levels. After this time, the effect of losing weight on blood cholesterol begin to show up and help decrease his *total to HDL cholesterol ratio* even further.

At the end of the simulation, he loses about 6 kg, his ratio decreases to 4.9 from 5.9, and his total cholesterol decreases to 179.5 mg/dL from 186.6 mg/dL, whereas his HDLC level increases to 36.3 mg/dL from 31.5 mg/dL. Keeping in mind that 1 per cent increase in HDLC level means 2-3 per cent less chance of hearth stroke; it is possible to argue that doing exercise is highly beneficial to the health of the subject.

Atheroprotective properties of HDL increase with exercise, but this is out of the model boundary and is not modeled. But it's already possible to conclude that doing more exercise is healthier than merely eating less by comparing the figures and numbers of the two losing weight scenarios. Exercise lowers the ratio to 4.95 and total cholesterol to 179.5 mg/dL, whereas diet decreases the ratio and total cholesterol to 5.35 and 173.5 mg/dL respectively. Total cholesterol in the second scenario is 6 mg/dL higher than the first one, yet it would be erroneous to jump to the conclusion that exercise is not a better solution than diet, because 4 mg/dL of this number adds to the HDLC level of the subject and only about 2 to the other cholesterol stocks in the blood and looking for the *total to HDL cholesterol ratio* is a more appropriate way of assessing the healthiness in terms of cholesterol levels.

6.1.4. More Exercise, More Dietary Intake – Constant Weight

In this case the subject exercises 150 kcal more than the base level while increasing his diet by the same calories. He is assumed to be increasing his entire dietary intake proportionately, namely by 7.67 per cent. His dietary fibers and cholesterol are assumed to be increasing by the same per cent. The results follow:



Figure 6.13 More Exercise, Constant Weight – Blood Cholesterol Levels



Figure 6.14 More Exercise, Constant Weight – Body Weight, Total Cholesterol and Cholesterol Ratio

It can be concluded from the figures and numbers that losing weight by any of the two methods in the earlier scenarios is more efficient in getting healthier numbers than this scenario, after noting that this scenario is better than the *do nothing* or the *base run*. In this constant weight scenario his total to HDLC cholesterol ratio decreases to 5.43 from 5.9; total cholesterol increases by 5 mg/dL of 4 mg/dL of which was in HDLC.

6.2. Hypercholesterolemic Subjects

6.2.1. Base Run

As an extension to the model, familial hypercholesterolemia (FH) can be simulated. In this type of cholesterol disorder, the LDL receptor activity of the patients' is reduced to half. Nearly 50 per cent of the receptors are not functioning (Bhagavan, 2002; Citkowitz, 2007). Reducing the LDL receptor activity results in lesser IDLC and LDLC uptakes by hepatic and extrahepatic tissues. HDLC and VLDLC don't seem to change but IDLC and LDLC rise to 28.0 mg/dL and 269.3 mg/dL from 18.5 mg/dL, and 111.5 mg/dL respectively. The total blood cholesterol increases to 353.9 mg/dL from 187 mg/dL. The total cholesterol levels of familial hypercholesterolemic patients' are between 330 and 400 mg/dL, and the model is able to reflect this change. Moreover total to HDL cholesterol ratio increases to 11.2 from 5.9. The base run can be seen after changing the stocks to their

new equilibrium levels and re-running the simulation as reported in the following graphs. All of the equations and the parameters can be seen in Appendix B.



Figure 6.15 Hypercholesterolemia Base Run – Blood Cholesterol Levels



Figure 6.16 FH Base Run – Body Weight, Total Cholesterol and Cholesterol Ratio

6.2.2. Increased Exercise, Reduced Dietary Intake

In this scenario, the patient tries to do more exercise and eat less. He does 150 kcal worth of exercise each day and has motivation to cut his diet by 50 kcal a day. The results can be seen in the following figures.



Figure 6.17 Hypercholesterolemia, More Exercise, Less Dietary Intake - Blood Cholesterol Levels

Figure 6.18 FH More Exercise Less Dietary Intake - Body Weight, Total Cholesterol and Cholesterol Ratio

By this diet and exercise program he loses about 8 kg. His total cholesterol level decreased to 324 mg/dL and his HDLC level increased 4 mg/dL. His *total to HDL cholesterol ratio* decreased to 8.9 from 11.2. Though there is a significant decrease, 8.9 is still a risky number (Harvard Health Letter, 2004), it should be lower than 7.0 to count as not risky.

6.2.3. Medication

Reducing the dietary intake and doing more exercising may not be not enough to reach to healthy cholesterol levels. Medicine is another option and the patient is assumed to take statins for this purpose. Statins lower or block the synthesis of cholesterol within liver and extrahepatic tissues by inhibiting HmG-CoA reductase – which is an enzyme in the production of cholesterol (Bhagavan, 2002), (Law, Wald, & Rudnicka, 2003).

The effect of statin in the model is by four factors. It is assumed that the given dose decreases the cholesterol synthesis in the liver and extrahepatic tissues by 300 mg/dL, and 100 mg/dL respectively. Also the metabolic adjustment times in these compartments to reach desired levels of intracellular cholesterol is increased to 2 and 4 days from 0.5 and 2 days in the liver and extrahepatic tissues.

The model as in the real case works like the following. First, statins lower the cholesterol synthesis in these tissues. So, the receptor activities of these tissues increase to compensate this loss. As a final result, more cholesterol is taken up by these tissues and blood cholesterol is thus decreased. This argument can be seen in Figure 6.19.

The total effect of statins is observed after about 4 weeks. This is reported in literature- as the time to see the full potential of statins is 4 weeks (Citkowitz, 2007; Statins, FM, 2008). The remarkable thing here is that we did not include any delay formulation to our model to reflect this 4 week period. Our model successfully gave this result with its parameters and structure unchanged for this purpose. This is sort of a validity check which is successfull but not intended.



Figure 6.19 Effect of Statins on Cholesterol Pools and Receptor Activities

Total cholesterol level decreased to 265 mg/dL, while *total to HDL cholesterol ratio* decreased to 8.4 from 11.2. Though this decrease is better than the lifestyle change in the previous experiment, it is still not sufficient alone. These findings can be found in the following figures.



Figure 6.20 Hypercholesterolemia, Medication Case- Blood Cholesterol Levels

Figure 6.21 FH Medication - Body Weight, Total Cholesterol and Cholesterol Ratio

6.2.4. Taking Medication, More Exercise, and Reduced Dietary Intake

As seen in the above two scenarios, neither taking medication nor changing the lifestyle alone provide sufficient results. So in this case, these two practices will be tried together as it is recommended to familial hypercholesterolemia patients by practitioners in the real world. So he will practice more that his daily exercise is increased by 150 kcal, dietary intake is reduced by 50 kcal, and he takes the same dose of statins as in the above scenario.

This combination is able to lower total cholesterol to 244 mg/dL and the total to HDL cholesterol ratio to 6.7. These numbers are regarded as borderline high, but a lot healthier than the patient's base run values: 354 mg/dL and a ratio of 11.2. The following figures depict this argument.



Figure 6.22 Hypercholesterolemia, Medication, Exercise, and Diet Case- Blood Cholesterol Levels



Figure 6.23 FH Medication, Exercise, and Diet Case- Body Weight, Total Cholesterol and Cholesterol Ratio

7. CONCLUSION

As stated in the introduction chapter, cholesterol has been the subject of many studies. In terms of methodology, there are simulation modeling studies and mathematical modeling studies. Simulation studies generally try to answer questions at the cellular level, whereas most mathematical models sacrifice model realism for the sake of analytical

tractability (August, Parker, & Barahona, 2007). Our model is built using system dynamics methodology and it has a systemic a view which takes diet, exercise, and the genetics of the person into account.

Reference simulation run for a healthy patient generates an adequate stable pattern for the variables of interest: HDL cholesterol, IDL cholesterol, LDL cholesterol, VLDL cholesterol, and body weight. Validity checks on a sector by sector basis and on the whole model give no signal of modeling flaws. Moreover, all sectors and the whole model are shown to be robust to random errors in the parameters. Likewise, the simulation run for the hypercholesterolemic patient case successfully generates the behavior of the disorder dynamics.

For healthy subjects, scenario runs include different settings like adding hazelnuts to the patient's diet, replacing carbohydrates with hazelnuts in the diet, weight loss by reducing dietary intake, weight loss by increasing the amount of exercise, and adding calories to the diet together with increased exercise to keep a constant body weight. When hazelnuts are added to the diet better cholesterol levels are first observed in the short run, while in the long run this situation is reversed since the patient gains weight. If the total caloric intake is kept constant while adding hazelnuts to the diet, the patient reaches healthier cholesterol levels both in the short and long terms. When the subject loses weight by reducing the caloric intake, we first observe a higher (worse) total cholesterol to HDL cholesterol ratio. This is due to sharper decrease in HDLC compared to other blood cholesterol pools as a response to decreased fat intake and is consistent with the literature (Mensink, Zock, Kester, & Katan, 2003). As the subject loses weight, HDLC increases while LDLC decreases, so the ratio reduces to values lower than the initial case. If the subject loses weight by increasing his daily exercise, he obtains even healthier results than the reduced dietary intake case. If the subject does more exercise but compensates this energy loss by eating more, she gets healthier cholesterol measures than the do-nothing case (base run), but worse results than any of the weight losing scenarios.

In the case of hypercholesterolemic subjects, the scenarios include the subject losing weight by increased exercise and reduced caloric intake, medication (taking statins), and the combination of medication, reduced caloric intake, and increased exercise. In the

medication scenario, the subject takes *statins* to lower her cholesterol. The full effect of statins is observed after 4 weeks of starting the medication and this is in agreement with what is observed in the real world (Statins, FM, 2008; Citkowitz, 2007). The remarkable thing here is that we did not include any delay formulation to our model to reflect this 4 week period. Our model successfully gave this result with its parameters and structure unchanged for this purpose. This is sort of a validity check which is successfull but not intended. Although statins result in healthier cholesterol levels than the first scenario (only losing weight), they, by themselves, are not enough to attain acceptable blood cholesterol levels. In the third scenario, the combination of medication, diet, and exercise are employed, yielding acceptable cholesterol levels which are clearly healthier than the results of all of the other scenarios.

Our model can be used to test other scenarios on both healthy and hypercholesterolemic subjects. The model can also be used as a foundation for a more comprehensive model that takes stress on both behavioral and physiological grounds into account. The subject, whose bodily dynamics are modeled in this study, is sort of a representative individual. His parameter values are average values of various individuals which are extracted from the literature. So, as an extension to this study, our model could be calibrated in a way to represent the cholesterol dynamics of "specific" persons. Finally, our model can be a starting point of an interactive simulation game which focuses on the management of hypercholesterolemic patients, where users can experiment with alternative diet, exercise & medication combinations.

APPENDIX A: LIST OF EQUATIONS FOR THE BASE RUN

Blood

HDLC(t) = HDLC(t - dt) + (Cholesterol_Uptake_by_HDL - HDLC_Transport__to_Liver - CETP_Regulated_C_Transfer) * dt

INIT HDLC = 31.555
INFLOWS:
Cholesterol_Uptake_by_HDL (IN SECTOR: Extrahepatic Tissue)
OUTFLOWS:
HDLC_Transport__to_Liver (IN SECTOR: Liver)
CETP_Regulated_C_Transfer = HDLC*CETP_Activity_Rate
IDLC(t) = IDLC(t - dt) + (VLDL_Turnover - IDL_Turnover -
Extrahepatic_Uptake__of_IDL - Hepatic_Uptake_of_IDL) * dt
INIT IDLC = 18.575
INFLOWS:
VLDL_Turnover = VLDLC*VLDL_Turnover_Rate
OUTFLOWS:
IDL_Turnover = IDLC*IDL_Turnover_Rate
Extrahepatic_Uptake__of_IDL =
IDLC*Effect_of_ET_Receptor_Activity_on_IDL_Uptake
Hepatic_Uptake_of_IDL = IDLC*Effect_of_HP_Receptor_Activity_on_IDL_Uptake
LDLC(t) = LDLC(t - dt) + (IDL_Turnover -
Extrahepatic__Uptake_of_LDL_by_Receptor_Dependent_Activity -
Hepatic_Uptake_of_LDL -
Extrahepatic_Uptake_of_LDL_by_Receptor_Independent_Activity) * dt
INIT LDLC = 111.45
INFLOWS:
IDL_Turnover = IDLC*IDL_Turnover_Rate
OUTFLOWS:
Extrahepatic__Uptake_of_LDL_by_Receptor_Dependent_Activity =
LDLC*Effect_of_ET_Receptor_Activity_on_LDL_Uptake
Hepatic_Uptake_of_LDL = LDLC*Effect_of_HP_Receptor_Activity_on_LDL_Uptake
+LDLC*Receptor_Indep_HP_Uptake_Rate
Extrahepatic_Uptake_of_LDL_by_Receptor_Independent_Activity =
LDLC*Receptor_Indep_ET_Uptake_Rate
VLDLC(t) = VLDLC(t - dt) + (VLDLC_Secretion + CETP_Regulated_C_Transfer -
VLDL_Turnover) * dt
INIT VLDLC = 25.0
INFLOWS:
VLDLC_Secretion =
Base_VLDLC_Secretion*Effect_of_Hepatic_Chol__Pool_on_VLDLC_Secretion
-9.18+Effect_of_Saturated_Fats_on_VLDLC_Secretion*Absorbed__Saturated_Fats
+12.97+Effect_of_Polyunsaturated_Fats_on_VLDLC_Secretion*Absorbed_Polyunsaturat
ed_Fats
+Effect_of_Body_Weight_on_VLDLC_Secretion
CETP_Regulated_C_Transfer = HDLC*CETP_Activity_Rate
OUTFLOWS:
VLDL_Turnover = VLDLC*VLDL_Turnover_Rate
CETP_Activity_Rate = 0.25
Effect_of_ET_Receptor_Activity_on_IDL_Uptake = ET_Receptor_Activity/60*5*0.3
Effect_of_ET_Receptor_Activity_on_LDL_Uptake = ET_Receptor_Activity/60*0.3*0.3
Effect_of_HP_Receptor_Activity_on_IDL_Uptake = (HP_Receptor_Activity/60)*5*0.7
Effect_of_HP_Receptor_Activity_on_LDL_Uptake = HP_Receptor_Activity/60*0.3*0.7
HDL_Removal_Time = 4

IDL_Turnover_Rate = 2.4
Normal_HDL_Efficiency = 15.78
Receptor_Indep_ET_Uptake_Rate = 0.1*0.3
Receptor_Indep_HP_Uptake_Rate = 0.1*0.7
Total_Chol_to_HDLC_ratio = total__cholesterol/HDLC
total__cholesterol = HDLC+IDLC+LDLC+VLDLC
VLDL_Turnover_Rate = 5.5

Body Weight

Basal_Metabolism(t) = Basal_Metabolism(t - dt) + (BM_Change) * dt
INIT Basal_Metabolism = 1800
INFLOWS:
BM_Change = (Base_Basal_Metabolism*Effect_of_Body_Weight_on_basal_metabolism-Basal_Metabolism)/BM_Change_Rate
+Metabolic_Adjustment_Effect
Body_Weight(t) = Body_Weight(t - dt) + (Weight_Change) * dt
INIT Body_Weight = 74
INFLOWS:
Weight_Change =
(Energy_Surplus_or_Shortage/Adjustment_Time_for_Weight_Change)/energy_kg_convertor
Adjustment_Time_for_Weight_Change = 1
Base_Basal_Metabolism = 1800
Base__Body_Weight = 74
BM_Change_Rate = 0.5
Effect_of_Body_Weight_on_VLDLC_Secretion = (Body_Weight-Base__Body_Weight)*1.95
Effect_of_Body__Weight_on__HDLC_Efficiency = (Base__Body_Weight-Body_Weight)*0.351
energy_kg_convertor = 7716
Energy_Surplus_or_Shortage = (Total_Available_Dietary_Energy-Total__Energy__Need)*Effect_of_Fat_Conversion_to_Energy_balance
Metabolic_Adjustment_Effect = (IF(Energy_Surplus_or_Shortage<=0) THEN
(Energy_Surplus_or_Shortage*Metabolic__Adjustment_Rate)
ELSE (0))
Metabolic__Adjustment_Rate = 0.1
Total_Available_Dietary_Energy =
((Absorbed_Polyunsaturated_Fats+Absorbed__Saturated_Fats+Absorbed_Monounsaturated_Fats)*energy_per_gr_fat+
Absorbed_Carbohydrates*energy_per_gr__carbondydrate+
Absorbed_Proteins*energy_per__gr_protein)*(1-Thermic_Effect_per_cent_of_Foods)
Total__Energy__Need = Basal_Metabolism+Exercise_and_Normal_Activities
Effect_of_Body_Weight_on_basal_metabolism =
GRAPH(Body_Weight/Base__Body_Weight)
(0.6, 0.563), (0.7, 0.628), (0.8, 0.73), (0.9, 0.897), (1, 1.00), (1.10, 1.05), (1.20, 1.11), (1.30, 1.16), (1.40, 1.21), (1.50, 1.29), (1.60, 1.40), (1.70, 1.53), (1.80, 1.70)
Effect_of_Fat_Conversion_to_Energy_balance =
GRAPH(Total_Available_Dietary_Energy/Total__Energy__Need)

(0.9, 1.00), (0.925, 1.00), (0.95, 1.01), (0.975, 1.02), (1.00, 1.04), (1.02, 1.08), (1.05, 1.11), (1.07, 1.16), (1.10, 1.20), (1.12, 1.22), (1.15, 1.24), (1.17, 1.25), (1.20, 1.25)

Diet and Exercise

Base_Level_of_High_Fibers = 10
Carbohydrate_Intake = 281.25
+step(281.25,5)*0
Cholesterol_Intake = 510
Exercise_and_Normal_Activities = 150
High_Fibers = 10
Monounsaturated_Fat_Intake = 50
+step(50,5)*0
Polyunsaturated_Fat_Intake = 25
+step(25,5)*0
Protein_Intake = 84.375
Saturated_Fat_intake = 12.5
+step(12.5,5)/2*0
Effect_of_Exercise_on_HDLC_Efficiency = GRAPH(Exercise_and_Normal_Activities)
(100, 0.00), (175, 0.8), (250, 2.10), (325, 3.78), (400, 4.83), (475, 5.31), (550, 5.52), (625, 5.64), (700, 5.67)

Digestive System

Bile_Chol(t) = Bile_Chol (t - dt) + (Bile_Secretion - Bile_Loss_in_Feces) * dt
INIT Bile_Chol = 3000
INFLOWS:
Bile_Secretion (IN SECTOR: Liver)
OUTFLOWS:
Bile_Loss_in_Feces = Base_Bile__Loss_Rate*Effect_of_High_Fibers_on_Bile_Loss
Absorbed_Carbohydrates = Carbohydrate_Intake*Normal_Carbohydrate_Absorption_Rate
Absorbed_Cholesterol =
Cholesterol_Intake*Normal_Cholesterol_Absorbtion_Ratio*Effect_of_Bile_on__Cholesterol_Absorbtion__per_cent
Absorbed_Monounsaturated_Fats =
Fat_Absorption__per_cent*Monounsaturated_Fat_Intake
Absorbed_Polyunsaturated_Fats = Fat_Absorption__per_cent*Polyunsaturated_Fat_Intake
Absorbed_Proteins = Normal_Protein_Absorption_Rate*Protein_Intake
Absorbed__Saturated_Fats = Fat_Absorption__per_cent*Saturated_Fat_intake
Base_Bile__Loss_Rate = 500
Effect_of_Bile_on__Cholesterol_Absorbtion__per_cent = Bile_Chol /Normal_Bile
Effect_of_Polyunsaturated_Fats_on_VLDLC_Secretion = -1.16*9/22.5/0.95
-0.23/4
Effect_of_Saturated_Fats_on_VLDLC_Secretion = 2.1*9/22.5/0.95
-0.442/4
energy_per_gr_fat = 9
energy_per_gr__carbondydrate = 4
energy_per__gr_protein = 4
Normal_Bile = 3000

Normal_Carbohydrate_Absorption_Rate = 0.99
Normal_Cholesterol_Absorbtion_Ratio = 0.55
Normal_Protein_Absorption_Rate = 0.90
Thermic_Effect_per_cent_of_Foods = 0.1
Effect_of_High_Fibers_on_Bile_Loss =
GRAPH(High_Fibers/Base_Level_of_High_Fibers)
(0.5, 0.939), (0.6, 0.941), (0.7, 0.946), (0.8, 0.955), (0.9, 0.975), (1, 1.00), (1.10, 1.03), (1.20, 1.06), (1.30, 1.09), (1.40, 1.10), (1.50, 1.10)
Fat_Absorption__per_cent = GRAPH(Bile_Chol /Normal_Bile)
(0.00, 0.00), (0.1, 0.175), (0.2, 0.465), (0.3, 0.73), (0.4, 0.84), (0.5, 0.9), (0.6, 0.93), (0.7, 0.937), (0.8, 0.943), (0.9, 0.947), (1, 0.95), (1.10, 0.951), (1.20, 0.951)

Extrahepatic Tissue

ET_Receptor_Activity(t) = ET_Receptor_Activity(t - dt) + (Receptor_Adaptation_in_ET) * dt
INIT ET_Receptor_Activity = 60
INFLOWS:
Receptor_Adaptation_in_ET =
Receptor_Surplus_or_Need_in_ET/ET_Receptor_Adjustment_Time
Intracellular_Cholesterol(t) = Intracellular_Cholesterol(t - dt) + (C_from_Blood + Metabolic_Chol_Effect - Cholesterol_Uptake_by_HDL - IC_Cellular_Usage) * dt
INIT Intracellular_Cholesterol = 1450
INFLOWS:
C_from_Blood =
Extrahepatic_Uptake__of_IDL+Extrahepatic__Uptake_of_LDL_by_Receptor_Dependent_Activity+Extrahepatic_Uptake_of_LDL_by_Receptor_Independent_Activity
Metabolic_Chol_Effect = (Normal_Chol_Level_in_Extrahepatic_Tissues-Intracellular_Cholesterol)/Metabolic_Chol_Effect_Adjustment_Time
OUTFLOWS:
Cholesterol_Uptake_by_HDL = Normal_HDL_Efficiency+
(Effect_of_Body__Weight_on__HDLC_Efficiency)*Normal_HDLC_Uptake_Rate+
(-0.5633+Effect_of_Exercise_on_HDLC_Efficiency)*Normal_HDLC_Uptake_Rate+
(-5.25+Effect_of_Saturated_Fats_on_HDLC_Efficiency*Absorbed__Saturated_Fats
-
5.50+Effect_of_Polyunsaturated_Fats_on_HDLC_Efficiency*Absorbed_Polyunsaturated_Fats
-
5+Effect_of_Monounsaturated_Fats_on_HDLC_Efficiency*Absorbed_Monounsaturated_Fats)*Normal_HDLC_Uptake_Rate
IC_Cellular_Usage =
Intracellular_Cholesterol/Normal_Chol_Level_in_Extrahepatic_Tissues*Base_IC__Cellular_Usage
Base_IC__Cellular_Usage = 25.463635
Effect_of_Monounsaturated_Fats_on_HDLC_Efficiency = 0.1/0.95
Effect_of_Polyunsaturated_Fats_on_HDLC_Efficiency = 0.22/0.95
Effect_of_Saturated_Fats_on_HDLC_Efficiency = 0.42/0.95
ET_Receptor_Adjustment_Time = 2.5
Metabolic_Chol_Effect_Adjustment_Time = 2

Normal_Chol_Level_in_Extrahepatic_Tissues = 1450
Normal_HDLC_Uptake_Rate = 1/2
Receptor_Surplus_or_Need_in_ET = (Receptor_Goal_in_Extrahepatic_Tissues-
ET_Receptor_Activity)
Receptor_Goal_in_Extrahepatic_Tissues =
GRAPH(Intracellular_Cholesterol/Normal_Chol_Level_in_Extrahepatic_Tissues)
(0.8, 75.0), (0.85, 75.0), (0.9, 71.3), (0.95, 67.0), (1.00, 60.0), (1.05, 50.0), (1.10, 42.5),
(1.15, 31.0), (1.20, 16.6), (1.25, 15.0), (1.30, 15.0)

Liver

Hepatic_Chol(t) = Hepatic_Chol(t - dt) + (Uptake__from_Blood +
Hepatic_Synthesis_Control + Chol_from__Diet - Bile_Secretion - VLDLC_Secretion) * dt
INIT Hepatic_Chol = 1700
INFLOWS:
Uptake__from_Blood =
Hepatic_Uptake_of_IDL+Hepatic_Uptake_of_LDL+HDLC_Transport__to_Liver
Hepatic_Synthesis_Control = (Normal_Chol__Level_in_Liver-
Hepatic_Chol)/Hepatic_Synthesis_Control_Rate
+245
Chol_from__Diet = Absorbed_Cholesterol
OUTFLOWS:
Bile_Secretion = Normal_Bile_Secretion*Effect_of_Hepatic__Chol_on_Bile__Secretion
+Bile_Discrepancy/Bile__Adjustment__Time
VLDLC_Secretion (IN SECTOR: Blood)
HP_Receptor_Activity(t) = HP_Receptor_Activity(t - dt) + (HP_Receptor_Adaptation) *
dt
INIT HP_Receptor_Activity = 60
INFLOWS:
HP_Receptor_Adaptation =
Receptor_Surplus_or_Need_in_Liver/HP_Receptor_Adaptation_Time
HDLC_Transport__to_Liver = HDLC/HDL_Removal_Time
OUTFLOW FROM: HDLC (IN SECTOR: Blood)
Base_VLDLC_Secretion = 137.5-7.884
Bile_Discrepancy = Normal_Bile- Bile_Chol
Bile__Adjustment__Time = 0.5
Hepatic_Synthesis_Control_Rate = 0.5
HP_Receptor_Adaptation_Time = 2.5
Normal_Bile_Secretion = 500
Normal_Chol__Level_in_Liver = 1700
Receptor_Surplus_or_Need_in_Liver = HP_Receptor_Goal-HP_Receptor_Activity
Effect_of_Hepatic_Chol__Pool_on_VLDLC_Secretion =
GRAPH(Hepatic_Chol/Normal_Chol__Level_in_Liver)
(0.75, 0.9), (0.8, 0.9), (0.85, 0.907), (0.9, 0.92), (0.95, 0.953), (1.00, 1.00), (1.05, 1.05),
(1.10, 1.10), (1.15, 1.13), (1.20, 1.15), (1.25, 1.15)
Effect_of_Hepatic__Chol_on_Bile__Secretion =
GRAPH(Hepatic_Chol/Normal_Chol__Level_in_Liver)
(0.00, 0.00), (0.1, 0.127), (0.2, 0.237), (0.3, 0.457), (0.4, 0.82), (0.5, 0.919), (0.6, 0.957),
(0.7, 0.979), (0.8, 0.989), (0.9, 0.995), (1, 1.00), (1.10, 1.00), (1.20, 1.00)

HP_Receptor_Goal = GRAPH(Hepatic_Chol/Normal_Chol__Level_in_Liver)
(0.8, 75.0), (0.85, 75.0), (0.9, 71.3), (0.95, 67.0), (1.00, 60.0), (1.05, 50.0), (1.10, 42.5), (1.15, 31.0), (1.20, 16.6), (1.25, 15.0), (1.30, 15.0)

APPENDIX B: LIST OF EQUATIONS FOR THE VALIDITY TESTS

Blood

HDLC(t) = HDLC(t - dt) + (Cholesterol_Uptake_by_HDL - HDLC_Transport__to_Liver - CETP_Regulated_C_Transfer) * dt
INIT HDLC = 52.64
INFLOWS:
Cholesterol_Uptake_by_HDL (IN SECTOR: Extrahepatic Tissue)
OUTFLOWS:
HDLC_Transport__to_Liver (IN SECTOR: Liver)
CETP_Regulated_C_Transfer = HDLC*CETP_Activity_Rate
IDLC(t) = IDLC(t - dt) + (VLDL_Turnover - IDL_Turnover - Extrahepatic_Uptake__of_IDL - Hepatic_Uptake_of_IDL) * dt
INIT IDLC = 18.445
INFLOWS:
VLDL_Turnover = VLDLC*VLDL_Turnover_Rate
OUTFLOWS:
IDL_Turnover = IDLC*IDL_Turnover_Rate
Extrahepatic_Uptake__of_IDL = IDLC*Effect_of_ET_Receptor_Activity_on_IDL_Uptake
Hepatic_Uptake_of_IDL = IDLC*Effect_of_HP_Receptor_Activity_on_IDL_Uptake
LDLC(t) = LDLC(t - dt) + (IDL_Turnover - Extrahepatic__Uptake_of_LDL_by_Receptor_Dependent_Activity - Hepatic_Uptake_of_LDL - Extrahepatic_Uptake_of_LDL_by_Receptor_Independent_Activity) * dt
INIT LDLC = 110.47
INFLOWS:
IDL_Turnover = IDLC*IDL_Turnover_Rate
OUTFLOWS:
Extrahepatic__Uptake_of_LDL_by_Receptor_Dependent_Activity = LDLC*Effect_of_ET_Receptor_Activity_on_LDL_Uptake
Hepatic_Uptake_of_LDL = LDLC*Effect_of_HP_Receptor_Activity_on_LDL_Uptake +LDLC*Receptor_Indep_HP_Uptake_Rate
Extrahepatic_Uptake_of_LDL_by_Receptor_Independent_Activity = LDLC*Receptor_Indep_ET_Uptake_Rate
VLDLC(t) = VLDLC(t - dt) + (VLDLC_Secretion + CETP_Regulated_C_Transfer - VLDL_Turnover) * dt
INIT VLDLC = 24.86
INFLOWS:
VLDLC_Secretion = Base_VLDLC_Secretion*Effect_of_Hepatic_Chol__Pool_on_VLDLC_Secretion -9.18+Effect_of_Saturated_Fats_on_VLDLC_Secretion*Absorbed__Saturated_Fats +12.97+Effect_of_Polyunsaturated_Fats_on_VLDLC_Secretion*Absorbed_Polyunsaturated_Fats +Effect_of_Body_Weight_on_VLDLC_Secretion

CETP_Regulated_C_Transfer = HDLC*CETP_Activity_Rate
OUTFLOWS:
VLDL_Turnover = VLDLC*VLDL_Turnover_Rate
CETP_Activity_Rate = 0.25
Effect_of_ET_Receptor_Activity_on_IDL_Uptake = ET_Receptor_Activity/60*5*0.3
Effect_of_ET_Receptor_Activity_on_LDL_Uptake = ET_Receptor_Activity/60*0.3*0.3
Effect_of_HP_Receptor_Activity_on_IDL_Uptake = (HP_Receptor_Activity/60)*5*0.7
Effect_of_HP_Receptor_Activity_on_LDL_Uptake = HP_Receptor_Activity/60*0.3*0.7
HDL_Removal_Time = 4
IDL_Turnover_Rate = 2.4
Normal_HDL_Efficiency = 15.78*54/34
+34.06/2*0
Receptor_Indep_ET_Uptake_Rate = 0.1*0.3
Receptor_Indep_HP_Uptake_Rate = 0.1*0.7
total_cholesterol = HDLC+IDLC+LDLC+VLDLC
Total_Chol_to_HDLC_ratio = total_cholesterol/HDLC
VLDL_Turnover_Rate = 5.5

Body Weight

Basal_Metabolism(t) = Basal_Metabolism(t - dt) + (BM_Change) * dt
INIT Basal_Metabolism = 1600
INFLOWS:
BM_Change = (Base_Basal_Metabolism*Effect_of_Body_Weight_on_basal_metabolism-Basal_Metabolism)/BM_Change_Rate
+Metabolic_Adjustment_Effect
Body_Weight(t) = Body_Weight(t - dt) + (Weight_Change) * dt
INIT Body_Weight = 94.4
INFLOWS:
Weight_Change =
(Energy_Surplus_or_Shortage/Adjustment_Time_for_Weight_Change)/energy_kg_convertor
Adjustment_Time_for_Weight_Change = 1
Base_Basal_Metabolism = 1600
Base__Body_Weight = 94.4
BM_Change_Rate = 0.5
Effect_of_Body_Weight_on_VLDLC_Secretion = (Body_Weight-Base__Body_Weight)*1.95
Effect_of_Body__Weight_on__HDLC_Efficiency = (Base__Body_Weight-Body_Weight)*0.351
energy_kg_convertor = 7716
Energy_Surplus_or_Shortage = (Total_Available_Dietary_Energy-Total__Energy__Need)*Effect_of_Fat_Conversion_to_Energy_balance
Metabolic_Adjustment_Effect = (IF(Energy_Surplus_or_Shortage<=0) THEN
(Energy_Surplus_or_Shortage*Metabolic__Adjustment_Rate)
ELSE (0))
Metabolic__Adjustment_Rate = 0.1

Total_Available_Dietary_Energy =
((Absorbed_Polyunsaturated_Fats+Absorbed__Saturated_Fats+Absorbed_Monounsaturated_Fats)*energy_per_gr_fat+
Absorbed_Carbohydrates*energy_per_gr__carbondydrate+
Absorbed_Proteins*energy_per__gr_protein)*(1-Thermic_Effect_per_cent_of_Foods)
Total__Energy__Need = Basal_Metabolism+Exercise_and_Normal_Activities
Effect_of_Body_Weight_on_basal_metabolism =
GRAPH(Body_Weight/Base__Body_Weight)
(0.6, 0.563), (0.7, 0.628), (0.8, 0.73), (0.9, 0.897), (1, 1.00), (1.10, 1.05), (1.20, 1.11), (1.30, 1.16), (1.40, 1.21), (1.50, 1.29), (1.60, 1.40), (1.70, 1.53), (1.80, 1.70)
Effect_of_Fat_Conversion_to_Energy_balance =
GRAPH(Total_Available_Dietary_Energy/Total__Energy__Need)
(0.9, 1.00), (0.925, 1.00), (0.95, 1.01), (0.975, 1.02), (1.00, 1.04), (1.02, 1.08), (1.05, 1.11), (1.07, 1.16), (1.10, 1.20), (1.12, 1.22), (1.15, 1.24), (1.17, 1.25), (1.20, 1.25)

Diet and Exercise

Base_Level_of_High_Fibers = 10
Carbohydrate_Intake = 254.5
+step(26.61,10)*0
Cholesterol_Intake = 510
Exercise_and_Normal_Activities = 154
High_Fibers = 10
Monounsaturated_Fat_Intake = 34.6
-step(19.33,10)*0
Polyunsaturated_Fat_Intake = 16.2
-step(5.91,10)*0
Protein_Intake = 76.7
-step(20.6,10)*0
Saturated_Fat_intake = 26.9
-step(13.34,10)*0
Effect_of_Exercise_on_HDLC_Efficiency = GRAPH(Exercise_and_Normal_Activities)
(100, 0.00), (175, 0.8), (250, 2.10), (325, 3.78), (400, 4.83), (475, 5.31), (550, 5.52), (625, 5.64), (700, 5.67)

Digestive System

Bile_Chol (t) = Bile_Chol (t - dt) + (Bile_Secretion - Bile_Loss_in_Feces) * dt
INIT Bile_Chol = 3000
INFLOWS:
Bile_Secretion (IN SECTOR: Liver)
OUTFLOWS:
Bile_Loss_in_Feces = Base_Bile__Loss_Rate*Effect_of_High_Fibers_on_Bile_Loss
Absorbed_Carbohydrates = Carbohydrate_Intake*Normal_Carbohydrate_Absorption_Rate
Absorbed_Cholesterol =
Cholesterol_Intake*Normal_Cholesterol_Absorbtion_Ratio*Effect_of_Bile_on__Cholesterol_Absorbtion__per_cent
Absorbed_Monounsaturated_Fats =
Fat_Absorption__per_cent*Monounsaturated_Fat_Intake

Absorbed_Polyunsaturated_Fats = Fat_Absorption__per_cent*Polyunsaturated_Fat_Intake
Absorbed_Proteins = Normal_Protein_Absorption_Rate*Protein_Intake
Absorbed__Saturated_Fats = Fat_Absorption__per_cent*Saturated_Fat_intake
Base_Bile__Loss_Rate = 500
Effect_of_Bile_on__Cholesterol_Absorbtion__per_cent = Bile_Chol /Normal_Bile
Effect_of_Polyunsaturated_Fats_on_VLDLC_Secretion = -1.16*9/22.5/0.95
-0.23/4
Effect_of_Saturated_Fats_on_VLDLC_Secretion = 2.1*9/22.5/0.95
-0.442/4
energy_per_gr_fat = 9
energy_per_gr__carbondydrate = 4
energy_per__gr_protein = 4
Normal_Bile = 3000
Normal_Carbohydrate_Absorption_Rate = 0.99
Normal_Cholesterol_Absorbtion_Ratio = 0.55
Normal_Protein_Absorption_Rate = 0.90
Thermic_Effect_per_cent_of_Foods = 0.1
Effect_of_High_Fibers_on_Bile_Loss =
GRAPH(High_Fibers/Base_Level_of_High_Fibers)
(0.5, 0.939), (0.6, 0.941), (0.7, 0.946), (0.8, 0.955), (0.9, 0.975), (1, 1.00), (1.10, 1.03), (1.20, 1.06), (1.30, 1.09), (1.40, 1.10), (1.50, 1.10)
Fat_Absorption__per_cent = GRAPH(Bile_Chol /Normal_Bile)
(0.00, 0.00), (0.1, 0.175), (0.2, 0.465), (0.3, 0.73), (0.4, 0.84), (0.5, 0.9), (0.6, 0.93), (0.7, 0.937), (0.8, 0.943), (0.9, 0.947), (1, 0.95), (1.10, 0.951), (1.20, 0.951)

Extrahepatic Tissue

ET_Receptor_Activity(t) = ET_Receptor_Activity(t - dt) + (Receptor_Adaptation_in_ET) * dt
INIT ET_Receptor_Activity = 61.82
INFLOWS:
Receptor_Adaptation_in_ET =
Receptor_Surplus_or_Need_in_ET/ET_Receptor_Adjustment_Time
Intracellular_Cholesterol(t) = Intracellular_Cholesterol(t - dt) + (C_from_Blood + Metabolic_Chol_Effect - Cholesterol_Uptake_by_HDL - IC_Cellular_Usage) * dt
INIT Intracellular_Cholesterol = 1431.32
INFLOWS:
C_from_Blood =
Extrahepatic_Uptake__of_IDL+Extrahepatic__Uptake_of_LDL_by_Receptor_Dependent_Activity+Extrahepatic_Uptake_of_LDL_by_Receptor_Independent_Activity
Metabolic_Chol_Effect = (Normal_Chol_Level_in_Extrahepatic_Tissues-Intracellular_Cholesterol)/Metabolic_Chol_Effect_Adjustment_Time
OUTFLOWS:
Cholesterol_Uptake_by_HDL = Normal_HDL_Efficiency+
(Effect_of_Body__Weight_on__HDLC_Efficiency)*Normal_HDLC_Uptake_Rate+
(-0.5633+Effect_of_Exercise_on_HDLC_Efficiency)*Normal_HDLC_Uptake_Rate+
(-5.25+Effect_of_Saturated_Fats_on_HDLC_Efficiency*Absorbed__Saturated_Fats

-
5.50+Effect_of_Polyunsaturated_Fats_on_HDLC_Efficiency*Absorbed_Polyunsaturated_Fats
-
5+Effect_of_Monounsaturated_Fats_on_HDLC_Efficiency*Absorbed_Monounsaturated_Fats)*Normal_HDLC_Uptake_Rate
IC_Cellular_Usage =
Intracellular_Cholesterol/Normal_Chol_Level_in_Extrahepatic_Tissues*Base_IC__Cellular_Usage
Base_IC__Cellular_Usage = 25.463635
Effect_of_Monounsaturated_Fats_on_HDLC_Efficiency = 0.1/0.95
Effect_of_Polyunsaturated_Fats_on_HDLC_Efficiency = 0.22/0.95
Effect_of_Saturated_Fats_on_HDLC_Efficiency = 0.42/0.95
ET_Receptor_Adjustment_Time = 2.5
Metabolic_Chol_Effect_Adjustment_Time = 2
Normal_Chol_Level_in_Extrahepatic_Tissues = 1450
Normal_HDLC_Uptake_Rate = 1/2
Receptor_Surplus_or_Need_in_ET = (Receptor_Goal_in_Extrahepatic_Tissues-ET_Receptor_Activity)
Receptor_Goal_in_Extrahepatic_Tissues =
GRAPH(Intracellular_Cholesterol/Normal_Chol_Level_in_Extrahepatic_Tissues)
(0.8, 75.0), (0.85, 75.0), (0.9, 71.3), (0.95, 67.0), (1.00, 60.0), (1.05, 50.0), (1.10, 42.5), (1.15, 31.0), (1.20, 16.6), (1.25, 15.0), (1.30, 15.0)

Liver

Hepatic_Chol(t) = Hepatic_Chol(t - dt) + (Uptake__from_Blood + Hepatic_Synthesis_Control + Chol_from__Diet - Bile_Secretion - VLDLC_Secretion) * dt
INIT Hepatic_Chol = 1704.79
INFLOWS:
Uptake__from_Blood =
Hepatic_Uptake_of_IDL+Hepatic_Uptake_of_LDL+HDLC_Transport__to_Liver
Hepatic_Synthesis_Control = (Normal_Chol__Level_in_Liver-Hepatic_Chol)/Hepatic_Synthesis_Control_Rate
+245
Chol_from__Diet = Absorbed_Cholesterol
OUTFLOWS:
Bile_Secretion = Normal_Bile_Secretion*Effect_of_Hepatic__Chol_on_Bile__Secretion
+Bile_Discrepancy/Bile__Adjustment__Time
VLDLC_Secretion (IN SECTOR: Blood)
HP_Receptor_Activity(t) = HP_Receptor_Activity(t - dt) + (HP_Receptor_Adaptation) * dt
INIT HP_Receptor_Activity = 59.44
INFLOWS:
HP_Receptor_Adaptation =
Receptor_Surplus_or_Need_in_Liver/HP_Receptor_Adaptation_Time
HDLC_Transport__to_Liver = HDLC/HDL_Removal_Time
OUTFLOW FROM: HDLC (IN SECTOR: Blood)
Base_VLDLC_Secretion = 137.5-7.884-1.5-20

Bile_Discrepancy = Normal_Bile- Bile_Chol
Bile__Adjustment__Time = 0.5
Hepatic_Synthesis_Control_Rate = 0.5
HP_Receptor_Adaptation_Time = 2.5
Normal_Bile_Secretion = 500
Normal_Chol__Level_in_Liver = 1700
Receptor_Surplus_or_Need_in_Liver = HP_Receptor_Goal-HP_Receptor_Activity
Effect_of_Hepatic_Chol__Pool_on_VLDLC_Secretion =
GRAPH(Hepatic_Chol/Normal_Chol__Level_in_Liver)
(0.75, 0.9), (0.8, 0.9), (0.85, 0.907), (0.9, 0.92), (0.95, 0.953), (1.00, 1.00), (1.05, 1.05), (1.10, 1.10), (1.15, 1.13), (1.20, 1.15), (1.25, 1.15)
Effect_of_Hepatic__Chol_on_Bile__Secretion =
GRAPH(Hepatic_Chol/Normal_Chol__Level_in_Liver)
(0.00, 0.00), (0.1, 0.127), (0.2, 0.237), (0.3, 0.457), (0.4, 0.82), (0.5, 0.919), (0.6, 0.957), (0.7, 0.979), (0.8, 0.989), (0.9, 0.995), (1, 1.00), (1.10, 1.00), (1.20, 1.00)
HP_Receptor_Goal = GRAPH(Hepatic_Chol/Normal_Chol__Level_in_Liver)
(0.8, 75.0), (0.85, 75.0), (0.9, 71.3), (0.95, 67.0), (1.00, 60.0), (1.05, 50.0), (1.10, 42.5), (1.15, 31.0), (1.20, 16.6), (1.25, 15.0), (1.30, 15.0)

Not in a sector

APPENDIX C: LIST OF EQUATIONS FOR THE FAMILIAL HYPERCHOLESTEROLEMIC CASE

Blood

HDLC(t) = HDLC(t - dt) + (Cholesterol_Uptake_by_HDL - HDLC_Transport__to_Liver - CETP_Regulated_C_Transfer) * dt
INIT HDLC = 31.555
INFLOWS:
Cholesterol_Uptake_by_HDL (IN SECTOR: Extrahepatic Tissue)
OUTFLOWS:
HDLC_Transport__to_Liver (IN SECTOR: Liver)
CETP_Regulated_C_Transfer = HDLC*CETP_Activity_Rate
IDLC(t) = IDLC(t - dt) + (VLDL_Turnover - IDL_Turnover - Extrahepatic_Uptake__of_IDL - Hepatic_Uptake_of_IDL) * dt
INIT IDLC = 18.575
INFLOWS:
VLDL_Turnover = VLDLC*VLDL_Turnover_Rate
OUTFLOWS:
IDL_Turnover = IDLC*IDL_Turnover_Rate
Extrahepatic_Uptake__of_IDL = IDLC*Effect_of_ET_Receptor_Activity_on_IDL_Uptake
Hepatic_Uptake_of_IDL = IDLC*Effect_of_HP_Receptor_Activity_on_IDL_Uptake
LDLC(t) = LDLC(t - dt) + (IDL_Turnover - Extrahepatic__Uptake_of_LDL_by_Receptor_Dependent_Activity - Hepatic_Uptake_of_LDL - Extrahepatic_Uptake_of_LDL_by_Receptor_Independent_Activity) * dt
INIT LDLC = 111.45
INFLOWS:
IDL_Turnover = IDLC*IDL_Turnover_Rate
OUTFLOWS:
Extrahepatic__Uptake_of_LDL_by_Receptor_Dependent_Activity = LDLC*Effect_of_ET_Receptor_Activity_on_LDL_Uptake
Hepatic_Uptake_of_LDL = LDLC*Effect_of_HP_Receptor_Activity_on_LDL_Uptake +LDLC*Receptor_Indep_HP_Uptake_Rate
Extrahepatic_Uptake_of_LDL_by_Receptor_Independent_Activity = LDLC*Receptor_Indep_ET_Uptake_Rate
VLDLC(t) = VLDLC(t - dt) + (VLDLC_Secretion + CETP_Regulated_C_Transfer - VLDL_Turnover) * dt
INIT VLDLC = 25.0
INFLOWS:
VLDLC_Secretion = Base_VLDLC_Secretion*Effect_of_Hepatic_Chol__Pool_on_VLDLC_Secretion -9.18+Effect_of_Saturated_Fats_on_VLDLC_Secretion*Absorbed__Saturated_Fats +12.97+Effect_of_Polyunsaturated_Fats_on_VLDLC_Secretion*Absorbed_Polyunsaturated_Fats +Effect_of_Body_Weight_on_VLDLC_Secretion

CETP_Regulated_C_Transfer = HDLC*CETP_Activity_Rate
OUTFLOWS:
VLDL_Turnover = VLDLC*VLDL_Turnover_Rate
CETP_Activity_Rate = 0.25
Effect_of_ET_Receptor_Activity_on_IDL_Uptake = ET_Receptor_Activity/60*5*0.3
Effect_of_ET_Receptor_Activity_on_LDL_Uptake = ET_Receptor_Activity/60*0.3*0.3
Effect_of_HP_Receptor_Activity_on_IDL_Uptake = (HP_Receptor_Activity/60)*5*0.7
Effect_of_HP_Receptor_Activity_on_LDL_Uptake = HP_Receptor_Activity/60*0.3*0.7
HDL_Removal_Time = 4
IDL_Turnover_Rate = 2.4
Normal_HDL_Efficiency = 15.78
Receptor_Indep_ET_Uptake_Rate = 0.1*0.3
Receptor_Indep_HP_Uptake_Rate = 0.1*0.7
Total_Chol_to_HDLC_ratio = total__cholesterol/HDLC
total__cholesterol = HDLC+IDLC+LDLC+VLDLC
VLDL_Turnover_Rate = 5.5

Body Weight

Basal_Metabolism(t) = Basal_Metabolism(t - dt) + (BM_Change) * dt
INIT Basal_Metabolism = 1800
INFLOWS:
BM_Change = (Base_Basal_Metabolism*Effect_of_Body_Weight_on_basal_metabolism-Basal_Metabolism)/BM_Change_Rate
+Metabolic_Adjustment_Effect
Body_Weight(t) = Body_Weight(t - dt) + (Weight_Change) * dt
INIT Body_Weight = 74
INFLOWS:
Weight_Change = (Energy_Surplus_or_Shortage/Adjustment_Time_for_Weight_Change)/energy_kg_convertor
Adjustment_Time_for_Weight_Change = 1
Base_Basal_Metabolism = 1800
Base__Body_Weight = 74
BM_Change_Rate = 0.5
Effect_of_Body_Weight_on_VLDLC_Secretion = (Body_Weight-Base__Body_Weight)*1.95
Effect_of_Body__Weight_on__HDLC_Efficiency = (Base__Body_Weight-Body_Weight)*0.351
energy_kg_convertor = 7716
Energy_Surplus_or_Shortage = (Total_Available_Dietary_Energy-Total__Energy__Need)*Effect_of_Fat_Conversion_to_Energy_balance
Metabolic_Adjustment_Effect = (IF(Energy_Surplus_or_Shortage<=0) THEN (Energy_Surplus_or_Shortage*Metabolic__Adjustment_Rate)
ELSE (0))
Metabolic__Adjustment_Rate = 0.1
Total_Available_Dietary_Energy = ((Absorbed_Polyunsaturated_Fats+Absorbed__Saturated_Fats+Absorbed_Monounsaturated_Fats)*energy_per_gr_fat+

Absorbed_Carbohydrates*energy_per_gr__carbondydrate+
Absorbed_Proteins*energy_per__gr_protein)*(1-Thermic_Effect_per_cent_of_Foods)
Total__Energy__Need = Basal_Metabolism+Exercise_and_Normal_Activities
Effect_of_Body_Weight_on_basal_metabolism =
GRAPH(Body_Weight/Base__Body_Weight)
(0.6, 0.563), (0.7, 0.628), (0.8, 0.73), (0.9, 0.897), (1, 1.00), (1.10, 1.05), (1.20, 1.11), (1.30, 1.16), (1.40, 1.21), (1.50, 1.29), (1.60, 1.40), (1.70, 1.53), (1.80, 1.70)
Effect_of_Fat_Conversion_to_Energy_balance =
GRAPH(Total_Available_Dietary_Energy/Total__Energy__Need)
(0.9, 1.00), (0.925, 1.00), (0.95, 1.01), (0.975, 1.02), (1.00, 1.04), (1.02, 1.08), (1.05, 1.11), (1.07, 1.16), (1.10, 1.20), (1.12, 1.22), (1.15, 1.24), (1.17, 1.25), (1.20, 1.25)

Diet and Exercise

Base_Level_of_High_Fibers = 10
Carbohydrate_Intake = 281.25
+step(281.25,5)*0
Cholesterol_Intake = 510
Exercise_and_Normal_Activities = 150
High_Fibers = 10
Monounsaturated_Fat_Intake = 50
+step(50,5)*0
Polyunsaturated_Fat_Intake = 25
+step(25,5)*0
Protein_Intake = 84.375
Saturated_Fat_intake = 12.5
+step(12.5,5)/2*0
Effect_of_Exercise_on_HDLC_Efficiency = GRAPH(Exercise_and_Normal_Activities)
(100, 0.00), (175, 0.8), (250, 2.10), (325, 3.78), (400, 4.83), (475, 5.31), (550, 5.52), (625, 5.64), (700, 5.67)

Digestive System

Bile_Chol (t) = Bile_Chol (t - dt) + (Bile_Secretion - Bile_Loss_in_Feces) * dt
INIT Bile_Chol = 3000
INFLOWS:
Bile_Secretion (IN SECTOR: Liver)
OUTFLOWS:
Bile_Loss_in_Feces = Base_Bile__Loss_Rate*Effect_of_High_Fibers_on_Bile_Loss
Absorbed_Carbohydrates = Carbohydrate_Intake*Normal_Carbohydrate_Absorption_Rate
Absorbed_Cholesterol =
Cholesterol_Intake*Normal_Cholesterol_Absorbtion_Ratio*Effect_of_Bile_on__Cholesterol_Absorbtion__per_cent
Absorbed_Monounsaturated_Fats =
Fat_Absorption__per_cent*Monounsaturated_Fat_Intake
Absorbed_Polyunsaturated_Fats = Fat_Absorption__per_cent*Polyunsaturated_Fat_Intake
Absorbed_Proteins = Normal_Protein_Absorption_Rate*Protein_Intake
Absorbed__Saturated_Fats = Fat_Absorption__per_cent*Saturated_Fat_intake
Base_Bile__Loss_Rate = 500

Effect_of_Bile_on__Cholesterol_Absorbtion__per_cent = Bile_Chol /Normal_Bile
Effect_of_Polyunsaturated_Fats_on_VLDLC_Secretion = -1.16*9/22.5/0.95
-0.23/4
Effect_of_Saturated_Fats_on_VLDLC_Secretion = 2.1*9/22.5/0.95
-0.442/4
energy_per_gr_fat = 9
energy_per_gr__carbondydrate = 4
energy_per__gr_protein = 4
Normal_Bile = 3000
Normal_Carbohydrate_Absorption_Rate = 0.99
Normal_Cholesterol_Absorbtion_Ratio = 0.55
Normal_Protein_Absorption_Rate = 0.90
Thermic_Effect_per_cent_of_Foods = 0.1
Effect_of_High_Fibers_on_Bile_Loss =
GRAPH(High_Fibers/Base_Level_of_High_Fibers)
(0.5, 0.939), (0.6, 0.941), (0.7, 0.946), (0.8, 0.955), (0.9, 0.975), (1, 1.00), (1.10, 1.03), (1.20, 1.06), (1.30, 1.09), (1.40, 1.10), (1.50, 1.10)
Fat_Absorption__per_cent = GRAPH(Bile_Chol /Normal_Bile)
(0.00, 0.00), (0.1, 0.175), (0.2, 0.465), (0.3, 0.73), (0.4, 0.84), (0.5, 0.9), (0.6, 0.93), (0.7, 0.937), (0.8, 0.943), (0.9, 0.947), (1, 0.95), (1.10, 0.951), (1.20, 0.951)

Extrahepatic Tissue

ET_Receptor_Activity(t) = ET_Receptor_Activity(t - dt) + (Receptor_Adaptation_in_ET) * dt
INIT ET_Receptor_Activity = 60
INFLOWS:
Receptor_Adaptation_in_ET =
Receptor_Surplus_or_Need_in_ET/ET_Receptor_Adjustment_Time
Intracellular_Cholesterol(t) = Intracellular_Cholesterol(t - dt) + (C_from_Blood + Metabolic_Chol_Effect - Cholesterol_Uptake_by_HDL - IC_Cellular_Usage) * dt
INIT Intracellular_Cholesterol = 1450
INFLOWS:
C_from_Blood =
Extrahepatic_Uptake__of_IDL+Extrahepatic__Uptake_of_LDL_by_Receptor_Dependent_Activity+Extrahepatic_Uptake_of_LDL_by_Receptor_Independent_Activity
Metabolic_Chol_Effect = (Normal_Chol_Level_in_Extrahepatic_Tissues-Intracellular_Cholesterol)/Metabolic_Chol_Effect_Adjustment_Time
OUTFLOWS:
Cholesterol_Uptake_by_HDL = Normal_HDL_Efficiency+
(Effect_of_Body__Weight_on__HDLC_Efficiency)*Normal_HDLC_Uptake_Rate+
(-0.5633+Effect_of_Exercise_on_HDLC_Efficiency)*Normal_HDLC_Uptake_Rate+
(-5.25+Effect_of_Saturated_Fats_on_HDLC_Efficiency*Absorbed__Saturated_Fats
-
5.50+Effect_of_Polyunsaturated_Fats_on_HDLC_Efficiency*Absorbed_Polyunsaturated_Fats
-
5+Effect_of_Monounsaturated_Fats_on_HDLC_Efficiency*Absorbed_Monounsaturated_Fats)*Normal_HDLC_Uptake_Rate

IC_Cellular_Usage =
Intracellular_Cholesterol/Normal_Chol_Level_in_Extrahepatic_Tissues*Base_IC__Cellular_Usage
Base_IC__Cellular_Usage = 25.463635
Effect_of_Monounsaturated_Fats_on_HDLC_Efficiency = 0.1/0.95
Effect_of_Polyunsaturated_Fats_on_HDLC_Efficiency = 0.22/0.95
Effect_of_Saturated_Fats_on_HDLC_Efficiency = 0.42/0.95
ET_Receptor_Adjustment_Time = 2.5
Metabolic_Chol_Effect_Adjustment_Time = 2
Normal_Chol_Level_in_Extrahepatic_Tissues = 1450
Normal_HDLC_Uptake_Rate = 1/2
Receptor_Surplus_or_Need_in_ET = (Receptor_Goal_in_Extrahepatic_Tissues-ET_Receptor_Activity)
Receptor_Goal_in_Extrahepatic_Tissues =
GRAPH(Intracellular_Cholesterol/Normal_Chol_Level_in_Extrahepatic_Tissues)
(0.8, 75.0), (0.85, 75.0), (0.9, 71.3), (0.95, 67.0), (1.00, 60.0), (1.05, 50.0), (1.10, 42.5), (1.15, 31.0), (1.20, 16.6), (1.25, 15.0), (1.30, 15.0)

Liver

Hepatic_Chol(t) = Hepatic_Chol(t - dt) + (Uptake__from_Blood + Hepatic_Synthesis_Control + Chol_from__Diet - Bile_Secretion - VLDLC_Secretion) * dt
INIT Hepatic_Chol = 1700
INFLOWS:
Uptake__from_Blood =
Hepatic_Uptake_of_IDL+Hepatic_Uptake_of_LDL+HDLC_Transport__to_Liver
Hepatic_Synthesis_Control = (Normal_Chol__Level_in_Liver-Hepatic_Chol)/Hepatic_Synthesis_Control_Rate
+245
Chol_from__Diet = Absorbed_Cholesterol
OUTFLOWS:
Bile_Secretion = Normal_Bile_Secretion*Effect_of_Hepatic__Chol_on_Bile__Secretion
+Bile_Goal/Bile__Adjustment__Time
VLDLC_Secretion (IN SECTOR: Blood)
HP_Receptor_Activity(t) = HP_Receptor_Activity(t - dt) + (HP_Receptor_Adaptation) * dt
INIT HP_Receptor_Activity = 60
INFLOWS:
HP_Receptor_Adaptation =
Receptor_Surplus_or_Need_in_Liver/HP_Receptor_Adaptation_Time
HDLC_Transport__to_Liver = HDLC/HDL_Removal_Time
OUTFLOW FROM: HDLC (IN SECTOR: Blood)
Base_VLDLC_Secretion = 137.5-7.884
Bile_Goal = Normal_Bile- Bile_Chol
Bile__Adjustment__Time = 0.5
Hepatic_Synthesis_Control_Rate = 0.5
HP_Receptor_Adaptation_Time = 2.5
Normal_Bile_Secretion = 500
Normal_Chol__Level_in_Liver = 1700

Receptor_Surplus_or_Need_in_Liver = HP_Receptor_Goal-HP_Receptor_Activity
Effect_of_Hepatic_Chol__Pool_on_VLDLC_Secretion =
GRAPH(Hepatic_Chol/Normal_Chol__Level_in_Liver)
(0.75, 0.9), (0.8, 0.9), (0.85, 0.907), (0.9, 0.92), (0.95, 0.953), (1.00, 1.00), (1.05, 1.05),
(1.10, 1.10), (1.15, 1.13), (1.20, 1.15), (1.25, 1.15)
Effect_of_Hepatic__Chol_on_Bile__Secretion =
GRAPH(Hepatic_Chol/Normal_Chol__Level_in_Liver)
(0.00, 0.00), (0.1, 0.127), (0.2, 0.237), (0.3, 0.457), (0.4, 0.82), (0.5, 0.919), (0.6, 0.957),
(0.7, 0.979), (0.8, 0.989), (0.9, 0.995), (1, 1.00), (1.10, 1.00), (1.20, 1.00)
HP_Receptor_Goal = GRAPH(Hepatic_Chol/Normal_Chol__Level_in_Liver)
(0.8, 75.0), (0.85, 75.0), (0.9, 71.3), (0.95, 67.0), (1.00, 60.0), (1.05, 50.0), (1.10, 42.5),
(1.15, 31.0), (1.20, 16.6), (1.25, 15.0), (1.30, 15.0)

REFERENCES

Abdel-Hamid, Tarek K., 2002, "Modeling the Dynamics of Human Energy Regulation and its Implications for Obesity Treatment", *System Dynamics Review*, Vol. 18, pp. 431-471.

Aidels, M., 2002, *A Compartmental Model for Kinetics of Apolipoprotein B-100 and Triglycerides in Vldl1 and Vldl2 in Normolipidemic Subjects*, M.S. Thesis, Chalmers University of Technology.

August, E., K. H. Parker, and M. Barahona, 2007, "A Dynamical Model of Lipoprotein Metabolism", *Bulletin of Mathematical Biology*, Vol. 69, pp. 1233-1254.

Barter, Phlip, John Kastelein, Alistair Nunn, and Hobbs Richard, 2003, "High Density Lipoproteins and Atherosclerosis; the Unanswered Questions", *Atherosclerosis*, Vol. 168, No. 2, pp. 195-211.

Bhagavan, N. V., 2002, "Lipids II: Phospolipids, Glycosphingolipids, and Cholesterol.", in N. V. Bhagavan (eds), *Medical Biochemistry*, pp. 401-427, Harcourt Academic Press, San Diego.

Boudi, F. Brain, 2006, *Atherosclerosis*, http://www.emedicine.com/med/topic182.htm.

Burke, Lora E., Mindi A. Styn, Ann R. Steenkiste, Edvin Music, Melanie Warziski, and Jina Choo, 2006, "A Randomized Clinical Trial Testing Treatment Preference and Two Dietary Options in Behavioral Weight Management: Preliminary Results of the Impact of Diet at 6 Months -PREFER Study", *Obesity*, Vol. 14, pp. 2007-2017.

Citkowitz, E., 2007, *Familial Hypercholesterolemia*, www.emedicine.com/MED/topic 1072 .htm.

Cohen, David E., 2007, "Balancing Cholesterol Synthesis and Absorption in the Gastrointestinal Tract", *The National Lipid Association 2nd Annual Maters Submit,* Orlando, 3 November, pp. S1-S3.

Dattilo, Anne M, and PM. Kris-Etherton, 1992, "Effects of Weight Reduction on Blood Lipds and Lipoproteins: a Meta-Analysis", *The American Journal of Clinical Nutrition*, Vol. 56, pp. 320-328.

Diaz, E. O., A. M. Prentice, G.R. Goldberg, P.R. Murgatroyd, and W.A. Coward, 1992, "Metabolic Response to Experimental Overfeeding in Lean and Overweight Healthy Volunteers", *American Journal of Clinical Nutrition*, Vol. 56, pp. 641-655.

Dietschy, John M., Stephen D. Turley, and David K. Spady, 1993, "Role of Liver in the Maintenanceof Cholesterol and Low Density Lipoprotein Homeostasis in Different Animal Species, Including Humans", *Journal of Lipid Research*,Vol. 34, pp. 1637-1659.

Glass, C. K., and J.L. Witztum, 2001, "Atherosclerosis: The Road Ahead", *Cell*, Vol. 104, pp. 503-516.

Goldstein, J. L., and M. S. Brown, 1997, "The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor", *Cell,* Vol. 89, pp. 331-340.

Gotto Jr., A. M., J. Lenfant, R. Paoletti, and A. L. Catapano, 1997, *Multiple Risk Factors in Cardiovascular Disease: Strategies of Prevention of Coronery Hearth Disease, Cardiac Failure, and Stroke,* Kluver Academic Publishers, Dordrecht.

Guyton, A., et al., 1991, *Textbook of Medical Physiology,* Heinemann Medical Books Ltd., London.

Halverstadt, Amy, Dana A. Phares, Kenneth R. Wilund, Andrew P. Goldberg, and James M. Hagberg, 2007, "Endurance Exercise Training Raises High-Density Lipoprotein Cholesterol Lowers Small Low-Density Lipoprotein and Very-Low Density Lipoprotein Independent of Body Fat Phenotypes in Older Men and Women", *Metabolism Clinical and Experimental,* Vol. 56, pp. 444-450.

Hegsted, Mark D, Lynne M Ausman, Julia A Johnson, and Gerard E Dalla, 1993, "Dietary Fat and Serum Lipids: an Evaluation of the Experimental Data", *The American Journal of Clinical Nutrition*, Vol. 57, pp. 875-883.

Heyman, M.B., V.R. Young, P. Fuss, R. Tsay, L. Joseph, and S.B. Roberts, 1992, "Underfeeding and Body Weight Regulation in Normal-Weight Young Men", *American Journal of Physiology*, Vol. 263, pp. R250-R257.

Kwiterovich, Peter O., 2000, "The Metabolic Pathways of High-Density Lipoprotein, Low-Density Lipoprotein, and Triglycerides: A Current Review", *The American Journal of Cardiology*, Vol. 86, pp. 5L-10L.

Law, M. R., N J Wald, and A. R. Rudnicka, 2003, "Quantifying Effect of Statins on Low Density Lipoprotein Cholesterol, Ischaemic Heart Disease, and Stroke: Systematic Review and Meta-Analysis", *BMJ*, pp. 1-7.

Lin, Don S., and William E. Connor, 1980, "The Long Term Effects of Dietary Cholesterol upon the Plasma Lipids, Lipoproteins, Cholesterol, Absorbtion, and the Sterol Balance in Man", *Journal of Lipid Research*, Vol. 21, pp. 1042-1052.

Ma, Hongbao, 2006, "Cholesterol and Human Health", *The Journal of American Science*, Vol. 2, pp. 46-50.

Marrugat, Jaume, Roberto Elosua, Maria Isabel Covas, Luis Molina, and Juan Rubies-Prat, 1996, "Amount and Intensity of Physical Activity, Physical Fitness, and Serum Lipids in Men", *American Journal of Epidemiology*, pp. 562-569.

Mensink, Ronald P., Peter L. Zock, Arnold DM Kester, and Martijn B. Katan, 2003, "Effects of Dietary Fatty Acids and Carbodydrates on the Ratio of Serum Total to HDL Cholesterol and on Serum Lipids and Apolipoproteins: a Meta-Analysis of 60 Controlled Trials", *The American Journal of Clinical Nutrition*, Vol. 77, pp. 1146-1155.

Murray, K. R., 2006, "Cholesterol Synthesis, Transport, & Excretion", in Robert K. Murray, Daryl K. Granner and Victor W. Rodwell (eds), *Harper's Illustrated Biochemistry*, pp. 230-240, McGraw- Hill, New York.

Ohashi, R., H. Mu, X. Wang, Q. Yao, and C. Chen, 2005, "Reverse Cholesterol Transport and Cholesterol Efflux in Atherosclerosis", *Q J Med*, Vol. 98, pp. 845-856.

Olchawa, Beata, et al., 2004, "Physical Fitness and Reverse Cholesterol Transport", *Arterioscler Thromb Vassc Biol*, Vol. 24, pp. 1087-1091.

Packard, C. J., et al., 2000, "Apolipoprotein B Metabolism and the Distribution of VLDL and LDL Subfractions", *Journal of Lipid Research*, Vol. 41, pp. 305-317.

Ross, R., 1995, "Cell Biology of Atherosclerosis", *Annual Reviews*, Vol. 57, pp. 791-804.

Ross, R., 1993, "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s", *Nature*, Vol. 362, pp. 801-809.

Schwartz, Charles C., Loren A. Zech, Julie M. VandenBroek, and Patrick S. Cooper, 1993, "Cholesterol Kinetics in Subjects with Bile Fistula: Positive Relationship between Size of the Bile Acid Precursor Pool and Bile Acid Synthetic Rate", *J. Clin. Invest.*, Vol. 91, pp. 923-938.

Statins, FM. 2008, http://www.clinicalanswers.nhs.uk/index.cfm?question=5490.

Stein, Olga, and Yechezkiel Stein, 1999, "Atheroprotective Mechanisms of HDL", *Atherosclerosis*, Vol. 144, pp. 285-301.

Sterman, John D., 2000, *Business Dynamics: Systems Thinking and Modeling for a Complex World*, Irwin McGraw-Hill, Boston.

Tall, Alan R., 1990, "Plasma High Density Lipoproteins", *The American Society for Clinical Investigation*, pp. 379-384.

Trejo-Gutierrez, Jorge F., and Gerald Fletcher, 2007, "Impact of Exercise on Blood Lipids and Lipoproteins", *Journal of Clinical Lipidology*, Vol. 1, pp. 175-181.

Weinsier, RL, D. Bracco, and Y. Schultz, 1993, "Predicted Effects of Small Decreases in Energy Expenditure On Weight Gain on Adult Women", *International Journal of Obesity*, Vol. 17, pp. 693-699.

Westerterp, Klaas R., Jeroen H.H.L.M. Donkers, Elizabeth W.H.M. Fredrix, and Piet Boekhoudt, 1994, "Energy Intake, Physical Activity and Body Weight: a Simulation Model", *British Journal of Nutrition*, Vol. 73, pp. 337-347.

"Which Cholesterol Test You Should Get", *Harvard Health Letter*, 2004, Vol. 30, pp. 4-5, November.

Whitney, EN., and SR. Rolfes, 1989, *Understanding Nutrition*, West/Wadsworth, Bemont.

Ylä-Herttuala, S., et al., 1989, "Evidence for the Presence of Oxidatively Modified Low Density Lipoprotein in Atherosclerotic Lesions of Rabbit and Man", *J Clin Invest*, Vol. 84, pp. 1086–1095.